Clinical and Molecular Hepatology

"AI"

Review

Severe hepatitis B flare and liver failure: current assessment and management: Seng Gee Lim, Maria Buti, Jordan J. Feld, James Fung, Adam J. Gehring, K. Rajender Reddy; Clin Mol Hepatol 2026;32(3):1117-1134.
Published online March 18, 2026; DOI: https://doi.org/10.3350/cmh.2026.0177

Hepatitis B flare is a common complication of chronic hepatitis B and is defined as an increase in HBV viral load associated with abnormal alanine aminotransferases (ALT), the consensus being an ALT level ≥5 times the upper limit of normal. The immunopathogenesis is related to induction of inflammatory cells and cytokines by the rise in HBV DNA. There are multiple causes of flares, and they carry the risk of progression to hepatic decompensation and acute-on-chronic liver failure (ACLF) with associated mortality, potentially requiring liver transplantation. Initial assessment should exclude other causes of liver dysfunction and determine severity and prognosis. General prognostic models of ACLF are useful but the COSSH-ACLF II score is specific to HBV. Early initiation of nucleos(t)ide analogues is crucial, even in severe HBV flares; it can reduce mortality by 73.6%. Once jaundice and coagulopathy occur, salvage by antivirals is challenging, and liver transplantation should be considered. However, many patients may not be suitable candidates for transplant or donor livers may not be available, as is common in Asia. Recently, there has been increasing evidence of the benefits of adjunctive therapies such as corticosteroids and plasma exchange, but there are associated risks and these approaches should be considered rescue therapies in severe HBV flares or ACLF. Liver transplant is the ultimate intervention when these other strategies fail. In summary, HBV flares are clinically serious events that can lead to hepatic decompensation, ACLF, and the need for a donor liver; however, strategies for rescue should be considered before liver transplantation.

3,332 View
165 Download

Correspondence

The lean phenotype in metabolic dysfunction-associated steatotic liver disease: diagnostic challenges and prognostic implications: Correspondence to editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations”: Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Dae Won Jun; Clin Mol Hepatol 2026;32(3):e389-e391.
Published online February 5, 2026; DOI: https://doi.org/10.3350/cmh.2026.0143

Citations

Citations to this article as recorded by

Rule-Out Cutoff of Two-Dimensional Shear Wave Elastography for Significant Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease: Systematic Review, Meta-Analysis, and External Validation
Joo Hyun Oh, Jonghyun Lee, Miyoung Choi, Kento Imajo, Masato Yoneda, Hideki Fujii, Hyo Young Lee, Eileen L. Yoon, Mimi Kim, Dae Won Jun
Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef

1,354 View
54 Download
1 Web of Science
Crossref

Letter to the Editor

Methodological considerations for lipidomic and fungal peptide-based risk stratification in acute liver failure: Letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure”: Hu Fu; Clin Mol Hepatol 2026;32(3):e283-e284.
Published online December 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.1387

890 View
60 Download

Review

Burden of malnutrition and sarcopenia in patients with cirrhosis: pathophysiology, assessment, and management: Takao Miwa, Masahito Shimizu, Bernd Schnabl; Clin Mol Hepatol 2026;32(2):487-510.
Published online December 16, 2025; DOI: https://doi.org/10.3350/cmh.2025.1126

Abstract
PDF

Malnutrition and sarcopenia are highly prevalent and robustly associated with reduced quality of life, disease progression, and poor outcomes, including complications and mortality, in patients with cirrhosis. Their pathophysiology is multifactorial, involving inadequate dietary intake and malabsorption, impaired liver functional reserves, altered energy, protein, and ammonia metabolism, systemic inflammation, hormonal dysregulation, and lifestyle or environmental influences. Despite extensive research, unresolved issues remain regarding optimal diagnostic criteria, as current approaches vary and lack global standardization. Regarding the diagnostic criteria for malnutrition, the usefulness of the Global Leadership Initiative on Malnutrition criteria has been proposed by international nutrition societies. However, evidence supporting their applicability in hepatology remains insufficient. For sarcopenia, differences in disease concept and diagnostic methods among societies indicate that no unified diagnostic standard exists, and clinicians should approach diagnosis with an understanding of the strengths and limitations of each method. Nutritional strategies emphasize adequate energy and protein intake, late evening snacks, and branched-chain amino acid supplementation, while deficiencies in micronutrients require tailored replacement. Nutritional therapy alone has limited effect on sarcopenia, but when combined with exercise it improves muscle mass, physical performance, and outcomes. Comprehensive approaches integrating optimized nutrition, micronutrient support, and structured exercise are essential to alleviate the burden of malnutrition and sarcopenia and to improve prognosis in patients with cirrhosis. This review addresses malnutrition and sarcopenia in cirrhosis by highlighting their prevalence, pathophysiology, clinical impact, and approaches for screening and diagnosis, and by emphasizing personalized nutritional, pharmacological, and exercise interventions to improve patient outcomes.

Citations

Citations to this article as recorded by

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis. Authors' reply
Yuki Utakata, Takao Miwa, Shinji Unome, Naoya Masuda, Mikita Oi, Masashi Aiba, Kenji Imai, Koji Takai, Makoto Shiraki, Naoki Katsumura, Masahito Shimizu
Alimentary Pharmacology & Therapeutics.2026; 63(9): 1329. CrossRef
Covert hepatic encephalopathy as a multi-organ syndrome: the gut–liver–muscle–brain axis, diagnosis, treatment, and multidisciplinary care
Takao Miwa, Cynthia L. Hsu, Masahito Shimizu, Patricia P. Bloom, Bernd Schnabl
Journal of Gastroenterology.2026; 61(9): 1217. CrossRef
Nutrition in cirrhosis: bridging guidelines and practice in hepatic disease
Jennifer Jin, Puneeta Tandon, Leah Gramlich
Current Opinion in Clinical Nutrition & Metabolic Care.2026; 29(5): 494. CrossRef
Letter: Major Adverse Outcomes in Steatotic Liver Disease Subtypes—From Etiological Classification to Biological Phenotyping: Authors' Reply
Takao Miwa, Bernd Schnabl
Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
A 12-week home-based exercise program with nutritional guidance is associated with improved functional capacity in chronic liver disease
Shinji Unome, Takao Miwa, Yoshihiko Atago, Satomi Nakashima, Kayoko Nishimura, Shinya Hiraoka, Masashi Aiba, Kenji Imai, Yohei Shirakami, Koji Takai, Takaaki Aoki, Masahito Shimizu
Clinical Nutrition ESPEN.2026; 75: 105073. CrossRef

6,056 View
364 Download
4 Web of Science
Crossref

Correspondence

Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”: Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji; Clin Mol Hepatol 2026;32(3):e346-e348.
Published online November 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.1218

1,243 View
40 Download

Editorial

Harmonized ACLF prognostication with explainable machine learning models: Traversing from counts to composition: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”: Sagnik Biswas, Akash Roy; Clin Mol Hepatol 2026;32(3):1386-1389.
Published online October 20, 2025; DOI: https://doi.org/10.3350/cmh.2025.1154

Citations

Citations to this article as recorded by

Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji
Clinical and Molecular Hepatology.2026; 32(3): e346. CrossRef

1,220 View
40 Download
1 Web of Science
Crossref

Letter to the Editor

Plasma exchange and abrogation of monocyte activation in Wilson’s disease: Letter to the editor on “Acute-on-chronic liver failure: Terminology, mechanisms and management”: Kwon Yong Tak, Min Seo Park, Pil Soo Sung; Clin Mol Hepatol 2026;32(3):e269-e273.
Published online October 13, 2025; DOI: https://doi.org/10.3350/cmh.2025.1039

1,571 View
143 Download

Correspondence

Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”: Changze Hong, Jinjun Chen; Clin Mol Hepatol 2026;32(3):e336-e338.
Published online September 29, 2025; DOI: https://doi.org/10.3350/cmh.2025.1063

1,003 View
13 Download

Editorial

Rethinking ACLF prognosis: Can machine learning outperform conventional scores?: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”: Jung Hee Kim; Clin Mol Hepatol 2026;32(3):1383-1385.
Published online September 23, 2025; DOI: https://doi.org/10.3350/cmh.2025.1053

Citations

Citations to this article as recorded by

Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji
Clinical and Molecular Hepatology.2026; 32(3): e346. CrossRef

1,659 View
85 Download
1 Web of Science
Crossref

Research Letter

Non-contrast magnetic resonance imaging outperforms contrast-enhanced computed tomography in preoperative detection of hepatocellular carcinoma: A paired validation study: Laizhu Zhang, Weiwei Zong, Jialin Gao, Huan Li, Leizhou Xia, Xiaoli Mai, Jun Chen, Binghua Li, Decai Yu; Clin Mol Hepatol 2026;32(1):e34-e37.
Published online September 17, 2025; DOI: https://doi.org/10.3350/cmh.2025.0927

2,035 View
123 Download

Correspondence

Impaired fungal surveillance with Kennedy pathway activation drives acute liver failure, validated in preclinical models: Correspondence to letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure”: Neha Sharma, Sushmita Pandey, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras; Clin Mol Hepatol 2026;32(3):e392-e395.
Published online September 15, 2025; DOI: https://doi.org/10.3350/cmh.2025.0970

1,026 View
41 Download

Editorial

Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”: Zhujun Cao, Richard Moreau; Clin Mol Hepatol 2026;32(2):953-956.
Published online September 1, 2025; DOI: https://doi.org/10.3350/cmh.2025.0962

Citations

Citations to this article as recorded by

Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Changze Hong, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(3): e336. CrossRef

3,234 View
51 Download
1 Web of Science
Crossref

Original Article

Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures: Yee Hui Yeo, Mengyi Zhang, Martin S. McCoy, Jian Zu, Yingli He, Yi Liu, Juan Li, Taotao Yan, Yuan Wang, Hirsh D. Trivedi, Ju Dong Yang, Vinay Sundaram, Xiaodan Sun, Zhujun Cao, Chun-Ying Wu, Jonel Trebicka, Fanpu Ji; Clin Mol Hepatol 2025;31(4):1355-1371.
Published online September 1, 2025; DOI: https://doi.org/10.3350/cmh.2025.0573

Background/Aims
Prediction of short-term mortality in patients with acute-on-chronic liver failure (ACLF) admitted to the intensive care unit (ICU) may enhance effective management.
Methods
To develop, explain, and validate a predictive machine learning (ML) model for short-term mortality in patients with ACLF with two or more organ failures (OFs). Utilizing a large ICU cohort with detailed clinical information, we identified ACLF patients with two or more OFs according to the EASL-CLIF and NACSELD definitions. ML model was developed for each definition to predict 30-day mortality. The Shapley value was estimated to explain the models. Validation and calibration of these models were performed.
Results
Of 5,994 patients with cirrhosis admitted to ICU, 1,511 met NACSELD criteria, and 1,692 met EASL-CLIF grade II or higher criteria. The CatBoost ACLF (CBA) model had the greatest accuracy in the NACSELD cohort (area under curve [AUC] of 0.87), while the Random Forest ACLF (RFA) model performed best in the EASL-CLIF cohort (AUC of 0.83). Both models showed robust calibration. The models were explained by SHAP score analysis, yielding a rank list, and the top twelve predictors were selected. Both simplified models demonstrated similar performance (CBA model: AUC 0.89, RFA model: AUC 0.81) and significantly outperformed contemporary scoring systems, including CLIF-C ACLF and MELD 3.0. The models were validated in both internal and external cohorts. A simple-to-use online tool was created to predict mortality rates.
Conclusions
We presented explainable, well-validated, and calibrated predictive models for ACLF patients with two or more OFs, which outperformed existing predictive scores.

Citations

Citations to this article as recorded by

Unbiased clustering of acute-on-chronic liver failure patients using machine learning in a real-world ICU cohort
Mengyi Zhang, Fanpu Ji, Jian Zu, Yingli He, Tao Chen, Yi Liu, Hirsh D. Trivedi, Ju Dong Yang, Vinay Sundaram, Yuan Wang, Xiaodan Sun, Zhujun Cao, Chun-Ying Wu, Yee Hui Yeo, Rajiv Jalan
Nature Communications.2026;[Epub] CrossRef
Systematic evaluation of machine learning models for clinical risk prediction on real-world hospital datasets
Qingwen Wu, Ziyou Qi, Qingwei Li, Cuiping Hao, Sujuan Tang
iScience.2026; 29(5): 115654. CrossRef
Navigating the therapeutic tightrope: Precision use of plasmapheresis and continuous renal replacement therapy in liver failure
Manish Manrai, Aditya V Pachisia, Saurabh Dawra, Siddharth Shukla, Atul A Jha
World Journal of Hepatology.2026;[Epub] CrossRef
Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease
Jonathan Soldera
Diagnostics.2026; 16(10): 1548. CrossRef
Gut–Liver Axis Failure in Critical Alcohol‐Associated Liver Disease: From ICU Secondary Hits to Microbiome‐Targeted Therapy
Yuting Zhang, Yiyu Wang, Yong Yang, Hong Mei, Xinxin Liu, Yuanxiu He, Song Qin, Banghai Feng, Ranjitsinh V. Devkar
Mediators of Inflammation.2026;[Epub] CrossRef
A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index
Yijun Zhang, Chunyan Li, Shaohui Su, Jilin Huang, Siyu Fu, Yong Zhang, Shanhong Tang
Frontiers in Medicine.2026;[Epub] CrossRef
Harmonized ACLF prognostication with explainable machine learning models: Traversing from counts to composition: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ fail
Sagnik Biswas, Akash Roy
Clinical and Molecular Hepatology.2026; 32(3): 1386. CrossRef
Rethinking ACLF prognosis: Can machine learning outperform conventional scores?: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
Jung Hee Kim
Clinical and Molecular Hepatology.2026; 32(3): 1383. CrossRef
Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji
Clinical and Molecular Hepatology.2026; 32(3): e346. CrossRef
Metabolomics and Machine Learning Uncover 5′-Methylthioadenosine as a Metabolic Indicator of Mixed-Pattern Drug-Induced Liver Injury
Jinghui Zhang, Hongchuan Liu, Qingrong Qiu, Kongcai Zhu, Xian Ding, Rui Zhao, Ting Hu, Zhuoling An
Metabolites.2026; 16(9): 614. CrossRef

7,916 View
457 Download
9 Web of Science
Crossref

Letter to the Editor

Plasma lipidomic and fungal signatures predict early mortality in acute liver failure: Yu Ji Kim, Jong-Won Kim; Clin Mol Hepatol 2026;32(1):e21-e23.
Published online August 20, 2025; DOI: https://doi.org/10.3350/cmh.2025.0813

Citations

Citations to this article as recorded by

Impaired fungal surveillance with Kennedy pathway activation drives acute liver failure, validated in preclinical models: Correspondence to letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatur
Neha Sharma, Sushmita Pandey, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
Clinical and Molecular Hepatology.2026; 32(3): e392. CrossRef

3,086 View
84 Download
1 Web of Science
Crossref

Research Letter

Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure: Wiramon Rungratanawanich, Ying Qu, Andrew Holmes, Neil Kaplowitz, Byoung-Joon Song; Clin Mol Hepatol 2026;32(1):e29-e33.
Published online August 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0748

Citations

Citations to this article as recorded by

Tissue-derived extracellular vesicles–mediated delivery of a hepatic enzyme living panorama (HELP) for treating multifactorial liver diseases
Xin Zeng, Wei Jiang, Baohong He, Lan Li, Tian Wu, Fudong Fu, Han Yao, Guangneng Liao, Chengshi Wang, Dongbo Wu
Journal of Nanobiotechnology.2026;[Epub] CrossRef
In silico molecular docking and in vivo evidence of whey protein concentrate-mediated protection against thioacetamide-induced intestinal toxicity in male albino rats via modulation of oxidative stress, inflammation, apoptosis, and fibrosis
Huda Fayez Al-Rashedi, Reem Alenazi, Nashmiah S. Alshammari, Mona A. Ibrahim, Sherif R. Mohamed, Hanan A. Okail
Frontiers in Nutrition.2026;[Epub] CrossRef

3,488 View
126 Download
3 Web of Science
Crossref

Editorial

Clinical implications of residual changes following HCV clearance: Editorial on “Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy”: So-Young Kim, Eui-Cheol Shin; Clin Mol Hepatol 2026;32(2):935-938.
Published online July 14, 2025; DOI: https://doi.org/10.3350/cmh.2025.0728

2,839 View
54 Download

Original Article

Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation: Changze Hong, Zuxiong Huang, Yingli He, Rongqi Wang, Jiaying Lin, Yushan Liu, Baicheng Liu, Xiaoqin Lan, Qinjun He, Wenfan Luo, Qintao Lai, Ling Zhou, Tingting Qi, Yali Ji, Miaoxia Liu, Qiaoping Wu, Yichen Yao, Weihao Liang, Xianbo Wang, Guohong Deng, Yanhang Gao, Yan Huang, Feng Liu, Xiaobo Lu, Zhongji Meng, Yuemin Nan, Hai Li, Beiling Li, Rajiv Jalan, Jinjun Chen; Clin Mol Hepatol 2025;31(4):1316-1332.
Published online July 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0332

Background/Aims
The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods
Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results
HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions
In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.

Citations

Citations to this article as recorded by

Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Zhujun Cao, Richard Moreau
Clinical and Molecular Hepatology.2026; 32(2): 953. CrossRef
Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Changze Hong, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(2): e227. CrossRef
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Norihiro Imai
Clinical and Molecular Hepatology.2026; 32(2): 949. CrossRef
Gestational and Congenital Toxoplasmosis: An Updated Review with Emphasis on High-Prevalence Countries
Alan Roberto Hatanaka, Antonio Braga, Evelyn Traina, Larissa Keren de Azevedo Teixeira, Carolina Longo, Pedro Teixeira Castro, Heron Werner, Gustavo Yano Callado, Edward Araujo Júnior
Women.2026; 6(3): 43. CrossRef

6,038 View
159 Download
5 Web of Science
Crossref

Correspondence

Correspondence to editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”: Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun; Clin Mol Hepatol 2026;32(1):e72-e74.
Published online April 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0350

Citations

Citations to this article as recorded by

GULP1: New hope for hepatocellular carcinoma: Reply to correspondence on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
Clinical and Molecular Hepatology.2026; 32(1): e112. CrossRef

3,154 View
40 Download
Crossref

Review

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum: Vishnu Girish, Rakhi Maiwall; Clin Mol Hepatol 2025;31(3):730-752.
Published online March 26, 2025; DOI: https://doi.org/10.3350/cmh.2024.1060

Abstract
PDF

Kidney disease in cirrhosis is now viewed as a continuum encompassing acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD), rather than three different disorders. Contemporary diagnostic criteria for AKI integrate urine output (UO) parameters and acknowledge the intricate relationship and possibility of overlap between functional and structural as well as acute and chronic entities, including hepatorenal syndrome (HRS). AKI demonstrates a propensity for progression to AKD and CKD, particularly in the context of recurrent and severe insults. The diagnostic complexity is further compounded by limitations in serum creatinine measurements, prompting the integration of novel biomarkers and the need to accurately estimate glomerular filtration rate. The diagnosis, phenotyping, and management of AKI should be prompt and early; the initial step should always be volume and UO assessment. A personalized approach is needed and the possibility of co-existing structural or functional kidney disease should be borne in mind. The earlier concept of waiting for 48 hours to diagnose HRS has evolved and early diagnosis and prompt treatment are advised now. Kidney replacement therapy and simultaneous liver and kidney transplantation may be required in resistant cases.

Citations

Citations to this article as recorded by

Comprehensive Conservative Management Versus Dialysis in Uric Acid Control
Francesca K. Martino, Greta Redi, Marco Bogo, Elena Sgrò, Alessandra Zattarin, Giovanni Samassa, Lucia Federica Stefanelli, Anna Basso, Federico Nalesso
Dietetics.2026; 5(1): 9. CrossRef
Renal Recovery Benefit of Living Versus Deceased Donor Liver Transplantation in Recipients With High Model for End-stage Liver Disease Scores: A Propensity Score-matched Study
Sung-Min Kim, Rak-Kyun Oh, Young-In Yoon, Won-Mook Choi, Shin Hwang, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Sung-Gyu Lee
Transplantation.2026; 110(5): e1016. CrossRef
Early prediction of acute kidney injury after therapeutic paracentesis in decompensated liver cirrhosis: diagnostic value of IL-18, KIM-1, and FGF-23
Ahmed Fayed, Ahmed Ramadan, Tarek Ramzy, Amr Shaker
Renal Failure.2026;[Epub] CrossRef
Risk factors for acute kidney injury in pediatric intensive care units: a systematic review and meta-analysis
Rong Li, Qianqian Yang
BMC Pediatrics.2026;[Epub] CrossRef
Molecular Biomarkers and Risk Prediction Models for Acute Kidney Injury Following Liver Transplantation: A Review
Bing Bin, Yuxiao Chen, Shijian Li, Jihua Wu
Journal of Clinical and Experimental Hepatology.2026; 16(4): 103550. CrossRef
Demographic and regional trends of mortality associated with hepatic cirrhosis and chronic kidney disease, in the United States, 1999-2020: A CDC WONDER database analysis
Mateen Ahmad, Ayman Irshad, Sahaab Noor, Humna Irshad, Muhammad Aliyan Ahmed
Journal of the National Medical Association.2026; 118(3): 525. CrossRef
Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers
Marti Ortega-Ribera, Robert Brenig, Christine Bernsmeier, Gyongyi Szabo
Journal of Hepatology.2026; 85(3): 612. CrossRef
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective
Florence Wong, Danielle Adebayo, Jacob George, Ramazan Idilman, Peter C Hayes, Mario R Alvares-da-Silva, Aldo Torre, Hailemichael Desalgn Mekonnen, Wai-Kay Seto, Shiv Kumar Sarin, Zhujun Cao, Neil Rajoriya, Aabha Nagral, Henok Fisseha, Anand V Kulkarni, C
Gut.2026; : gutjnl-2025-336802. CrossRef
Urinary Gas Chromatography‐Based Metabolomics for Early Detection of Liver Cirrhosis and Hepatocellular Carcinoma: A Decade of Progress
Diaa I. Osman, Sheta M. Sheta, Mostafa I. Abdelglil, Fatma O. Khalil, Waheed M. Salem, Naser A. Naser, Ahmed Attia
Biomedical Chromatography.2026;[Epub] CrossRef
Shear Wave Elastography Combined with ALBI Score Enhances Prediction of Hepatic Decompensation in Chronic Liver Disease
Jaejun Lee, Hyun Yang, Si Hyun Bae, Sun Hong Yoo, Soon Woo Nam, Jiwoon Yoon, Jung Hyun Kwon, Soon Kyu Lee
JHEP Reports.2026; : 101963. CrossRef
Machine learning-derived clinical phenotypes of ascites in cirrhosis: A multi-center latent class analysis with external validation
Giuseppe Cullaro, Jennifer C. Lai, Taryn Liu, Miguel E. Gomez, Douglas A. Simonetto, Sean Lee, Brian P. Lee, Andrew S. Allegretti, Nikhilesh R. Mazumder, Kavish R. Patidar, Elizabeth C. Verna
Liver Transplantation.2026;[Epub] CrossRef
Association between the C-reactive protein–triglyceride–glucose index (CTI) and the risk of acute kidney injury in critically ill patients with cirrhosis
Lu-Huai Feng, Tianbao Liao, Tingting Su, Xuefei Zhou, Yang Lu, Lina Huang, Zhenhua Yang
BMC Nephrology.2025;[Epub] CrossRef

12,517 View
285 Download
11 Web of Science
Crossref

Correspondence

Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”: Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun; Clin Mol Hepatol 2026;32(1):e103-e105.
Published online March 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.0287

6,139 View
55 Download

Reply to Correspondence

Viral hepatitis

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”: Chen-Hua Liu, Yu-Ping Chang; Clin Mol Hepatol 2025;31(2):e232-e233.
Published online February 26, 2025; DOI: https://doi.org/10.3350/cmh.2025.0203

5,828 View
26 Download

Original Articles

GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma: Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, Moon Gyeong Yoon, Geum Ok Baek, Minji Kang, Se Ha Jang, Won Park, Yunjin Go, Jestlin Tianthing Ng, Suk Woo Nam, Jee-Yeong Jeong, Ji Eun Han, Hyo Jung Cho, Su Bin Lim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun; Clin Mol Hepatol 2025;31(3):914-934.
Published online February 6, 2025; DOI: https://doi.org/10.3350/cmh.2024.1038

Background/Aims
Hepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC recurrence and evaluate the efficiency of GULP PTB domain-containing engulfment adaptor 1 (GULP1) as a predictive and diagnostic marker and therapeutic target for HCC.
Methods
We analyzed genomic datasets from The Cancer Genome Atlas and Gene Expression Omnibus databases via least absolute shrinkage and selection operator Cox regression and 10-fold cross-validation, leading to the development of a 15-gene risk score model, which was validated using three independent datasets. Serum GULP1 and α-fetoprotein levels were assessed to determine the diagnostic accuracy of the model. Using clinical cohorts and patient sera, GULP1 roles were examined, and functional assays in vitro and in vivo were used to evaluate its effects on cell growth, epithelial–mesenchymal transition (EMT), ADP-ribosylation factor 6 (ARF6) activation, and β-catenin signaling.
Results
Our newly developed risk-score model accurately predicted recurrent HCC in all datasets. Among the 15 genes in the risk score model, GULP1 was overexpressed in patients with HCC and independently predicted HCC recurrence. Its expression modulation influenced cell growth and EMT, with observed effects on ARF6 activation and β-catenin signaling pathways.
Conclusions
GULP1 is a crucial biomarker for HCC, serving as a non-invasive diagnostic and predictive tool. It also plays key roles in HCC progression. Our findings highlight the potential use of GULP1 in treatment strategies targeting EMT and HCC recurrence to improve the personalized care and patient outcomes.

Citations

Citations to this article as recorded by

Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Clinical and Molecular Hepatology.2026; 32(1): e103. CrossRef
GULP1, a multifaceted diagnostic biomarker and potential therapeutic target in hepatocellular carcinoma: Editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
Clinical and Molecular Hepatology.2026; 32(1): 413. CrossRef
Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Juan Yang, Xinyi Li, Sheng Zheng
Clinical and Molecular Hepatology.2026; 32(1): e10. CrossRef
GULP1: New hope for hepatocellular carcinoma: Reply to correspondence on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
Clinical and Molecular Hepatology.2026; 32(1): e112. CrossRef
Correspondence to editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun
Clinical and Molecular Hepatology.2026; 32(1): e72. CrossRef
Unveiling GULP1 as a hepatocyte-specific role for recurrence: Editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
Pengde Lu, Ning Wang
Clinical and Molecular Hepatology.2026; 32(1): 410. CrossRef
Identifying Immunological Biomarkers for Major Depressive Disorder: Insights From Machine Learning, Single‐Nucleus Bioinformatics, and Experimental Validation
Long Kangsheng, Yang Xiaohui, Pei Xin, Ye Yong, Li Hongliang, Deng Yihui, Poorani Gurumallesh Prabu
BioMed Research International.2026;[Epub] CrossRef
MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Suki Ha, Xiang Zhang, Lanjuan Li, Jun Yu
Science Bulletin.2026; 71(11): 2916. CrossRef
Reply to correspondence on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography”
Qi-Feng Chen, Sui-Xing Zhong, Xiong-Ying Jiang, Ming Zhao
Clinical and Molecular Hepatology.2026; 32(3): e441. CrossRef
Integrated Transcriptomic Analyses Identify Four Prognosis-Associated Genes in Hepatocellular Carcinoma
Yuxian Liu, Xingjie Chen, Junyuan Zhang, Xueyan Zhou, Xiaohui Li, Kangcheng Xu, Hao Lin, Yanni Cao
International Journal of Molecular Sciences.2026; 27(17): 7535. CrossRef
The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma
Xinyu Guo, Zhongwei Zhao, Lingyi Zhu, Shuang Liu, Lingling Zhou, Fazong Wu, Shiji Fang, Minjiang Chen, Liyun Zheng, Jiansong Ji
Biomarker Research.2025;[Epub] CrossRef
Advances in research regarding epithelial-mesenchymal transition and prostate cancer
Xi Wei, Rui Liu, Wei Li, Qi Yu, Qing Tao Yang, Tao Li
Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma
Xiyan Xiang, Kirti Shetty, Herbert Yu, Bibhuti Mishra, Linda L. Wong, Xianghong Jasmine Zhou, Sanjaya K. Satapathy, James M. Crawford, Patricia S. Latham, Steven‐Huy Han, Brandon Mathew, Nabil N. Dagher, Lawrence Lau, Fellanza Cacaj, Anil K. Vegesna, Srin
Liver International.2025;[Epub] CrossRef
Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer
Weihao Kong, Long Teng, Kangjie Zhang, Yajun Zou, Xingyu Wang, Jianlin Zhang
Biochemistry and Biophysics Reports.2025; 44: 102358. CrossRef

17,011 View
1,092 Download
15 Web of Science
Crossref

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study: Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bair, Te-Sheng Chang, Chun-Yen Lin, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzeng-Hue Yang, Cheng-Yuan Peng, Chi-Chieh Yang, Lee-Won Chong, Chien-Wei Huang, Chih-Wen Lin, Cheng-Hsin Chu, Ming-Chang Tsai, Jia-Horng Kao, Chun-Jen Liu, Wan-Long Chuang, Teng-Yu Lee, Ming-Lung Yu, on behalf of TACR investigators; Clin Mol Hepatol 2025;31(3):899-913.
Published online February 5, 2025; DOI: https://doi.org/10.3350/cmh.2024.1015

Background/Aims
The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C, remains largely uncertain. We aimed to explore the impact of DAA therapy on overall survival (OS) in HCC patients using a nationwide cohort study.
Methods
We utilized the nationwide Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) database to include all adults receiving a DAA therapy for HCV, excluding those with other viral infections, liver transplantation, non-HCC malignancies, and terminal-staged HCC. We respectively analyzed the adjusted odds ratio (aOR) for sustained virological response (SVR) and adjusted hazard ratio (aHR) for OS.
Results
Between December 2013 and December 2020, 2,205 (9.3%) patients with HCC and 21,569 (90.7%) patients without HCC were include. The SVR rates were 96.6% in the HCC group and 98.8% in the non-HCC group (P<0.001), with HCC being an independent risk factor affecting SVR (aOR 0.41; 95% CI 0.31–0.54; P<0.001). In the whole patient cohort, SVR was independently associated with improved OS (aHR 0.46; 95% CI 0.35–0.60; P<0.001). Among patients with baseline HCC, SVR remained an independent factor related to OS (aHR 0.41; 95% CI 0.28–0.59; P<0.001). The impact of SVR on OS persisted significantly across BCLC stages 0/A and stages B/C.
Conclusions
High SVR rates among HCC patients underscore the importance of DAA therapy in enhancing OS, reaffirming its efficacy across various HCC stages.

Citations

Citations to this article as recorded by

Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
Clinical and Molecular Hepatology.2026; 32(1): e99. CrossRef
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
Clinical and Molecular Hepatology.2026; 32(1): e68. CrossRef
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai
European Journal of Cancer.2026; 232: 116109. CrossRef
Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study”
Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen
Clinical and Molecular Hepatology.2026; 32(1): e7. CrossRef
Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC
María Fernanda Guerra‐Veloz, Sital Shah, Beatrice Emmanouil, Mia Olsen, Renita George, Sarah Selemani, Paul J. Ross, Ivana Carey, Neha Mehta, Mark Gillyon‐Powell, Kosh Agarwal
Journal of Viral Hepatitis.2026;[Epub] CrossRef
Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR. Authors' Reply
Yu‐Sheng Lin, Yun‐Yu Chen, Teng‐Yu Lee
Alimentary Pharmacology & Therapeutics.2026; 63(10): 1439. CrossRef
Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
Yu‐Sheng Lin, Hwai‐I Yang, Teng‐Yu Lee
Alimentary Pharmacology & Therapeutics.2026; 63(10): 1429. CrossRef
Letter: Beyond Association—Operationalising PRS‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
Yu‐Sheng Lin, Ying‐Cheng Lin, Teng‐Yu Lee
Alimentary Pharmacology & Therapeutics.2026; 63(10): 1443. CrossRef
HIV, Viral Hepatitis, and Schistosomiasis Association with Liver Cancer: A Systematic Review
Khumbuzile Canham, Pragalathan Naidoo, Sibusiso Senzani, Sayed Shakeel Kader, Zilungile L. Mkhize-Kwitshana
Microorganisms.2025; 13(12): 2753. CrossRef

15,007 View
236 Download
14 Web of Science
Crossref

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial: Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang; Clin Mol Hepatol 2025;31(3):810-822.
Published online January 17, 2025; DOI: https://doi.org/10.3350/cmh.2024.0819

Background/Aims
Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods
In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Results
The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions
In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.

Citations

Citations to this article as recorded by

Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Wai-Kay Seto
Clinical and Molecular Hepatology.2026; 32(1): 374. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk
Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim
Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu
World Journal of Gastroenterology.2025;[Epub] CrossRef

14,566 View
211 Download
3 Web of Science
Crossref

Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure: Neha Sharma, Sushmita Pandey, Gaurav Tripathi, Manisha Yadav, Nupur Sharma, Babu Mathew, Abhishak Gupta, Vasundhra Bindal, Sadam H. Bhat, Yash Magar, Rimsha Saif, Sanju Yadav, Amritpal Kaur, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras; Clin Mol Hepatol 2025;31(4):1233-1251.
Published online December 13, 2024; DOI: https://doi.org/10.3350/cmh.2024.0554

Background/Aims
Acute liver failure (ALF) has high mortality predominantly due to compromised immune system and increased vulnerability to bacterial and fungal infections.
Methods
Plasma lipidome and fungal peptide-based community (mycobiome) analysis were performed in discovery cohort (ALF=40, healthy=5) and validated in a validation cohort of 230 patients with ALF using high-resolution-mass-spectrometry, artificial neural network (ANN) and machine learning (ML).
Results
Untargeted lipidomics identified 2,013 lipids across 8 lipid group. 5 lipid-species—phosphatidylcholine (PC)[15:0/17:0], PC[20:1/14:1], PC[26:4/10:0], PC[32:0] and TG[4:0/10:0/23:6]—significantly differentiated ALF-NS (FC>10, P<0.05, FDR<0.01). Mycobiome alpha/beta diversity was significantly higher and showed 4 phyla and >20 species significantly dysregulated in ALF-NS linked with lipid metabolism, fatty acid elongation in ER, and others (P<0.05). Lipid and mycobiome diversity values in ALF-NS were strongly correlated (r²>0.7, P<0.05). Multi-modular correlation network showed striking associations between lipid, fungal peptide modules, and clinical parameters specific to ALF-NS (P<0.05). Cryptococcus amylolentus CBS6039 and Penicillium oxalicum 1142 directly correlated with phosphatidylcholine, triglycerides, and severity in ALF-NS (r²>0.85, P<0.05). POD-fungus and POD-lipids showed direct association with infection, necrosis, and hepatic encephalopathy (Beta>1.2, P<0.05). POD-lipid (AUC=0.969 and HR=1.99 [1.02–2.04]) superseded POD-fungus and severity indices for early-mortality prediction. Finally, significant increase in PC (15:0/17:0) level showed highest normalized importance, and ANNs and ML predicted early mortality with >95% accuracy, sensitivity, and specificity. Interestingly, fungal surveillance protein Clec7a was significantly downregulated (>2-fold), leading to a notable increase in fungal infection-mediated choline/phosphatidylcholine and associated enzymes (FC>1.5; Kennedy cycle). This contributed to phosphatidic acid-mediated hyper-inflammation in ALF-NS.
Conclusions
In ALF, the plasma lipidome and mycobiome are dysregulated. Increased circulating phosphatidylcholine could stratify ALF predisposed to early mortality or require emergency liver transplantation.

Citations

Citations to this article as recorded by

Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
S. K. Sarin, Ashok Choudhury, Anupam Kumar, Nadim Mahmud, G. H. Lee, Qin Ning, Soek-Siam Tan, Kessarin Thanapirom, Vinod Arora, Nobuaki Nakayama, Jun Li, Constantine J. Karvellas
Nature Reviews Gastroenterology & Hepatology.2026; 23(5): 411. CrossRef
Plasma lipidomic and fungal signatures predict early mortality in acute liver failure
Yu Ji Kim, Jong-Won Kim
Clinical and Molecular Hepatology.2026; 32(1): e21. CrossRef
Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia
Emily J. Mason, Jeremy M. Schraw, John P. Woodhouse, M. Monica Gramatges, Kevin J. Williams, Baojiang Chen, Melissa B. Harrell, Olga A. Taylor, Michael E. Scheurer, Philip J. Lupo, Karen R. Rabin, Joanna S. Yi, Van Huynh, Steven D. Mittelman, Etan Orgel,
Supportive Care in Cancer.2026;[Epub] CrossRef
The signatures and crosstalk of gut mycobiome, microbiome, and metabolites in drug-induced liver injury
Weiyan Huang, Yirui Hu, Zexuan Li, Jiake Che, Shuyan Wang, Ye Yang, Shengqi Yan, Yue Chen, Wenkang Gao, Fuyu Yang, Ting Wei, Kai Liu, Yuanqing Zhu, Yupin Tan, Yue Yang, Xinyang Wang, Yonggang Yuan, Zhuang Cao, Xiaotong Du, Jiahao Liu, Ling Yang, Huikuan C
Mycology.2026;[Epub] CrossRef
Distinct bile mycobiome signature identifies fungal peptide panel predictive for gallbladder carcinoma
Sanju Yadav, Nupur Sharma, Manisha Yadav, Neha Sharma, Gaurav Tripathi, Sadam H. Bhat, Sushmita Pandey, Babu Mathew, Vasundhra Bindal, Rimsha Saifi, Vipul Sharma, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras
Molecular Therapy Oncology.2026; 34(2): 201220. CrossRef
Impaired fungal surveillance with Kennedy pathway activation drives acute liver failure, validated in preclinical models: Correspondence to letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatur
Neha Sharma, Sushmita Pandey, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
Clinical and Molecular Hepatology.2026; 32(3): e392. CrossRef
Endogenous phosphatidylcholine 16:0/20:4 increases to promote liver regeneration in hepatectomy
Luze Cen, Ying Wang, Jie Yang, Wenbo Shi, Pengyao Lin, Weiqi Zhang, Xiaobo Xiang, Xinchang Gao, Jing Huang, Jiongze Fang, Xi Yu, Manyun Dai, Aiming Liu, Caide Lu
iScience.2026; 29(8): 116962. CrossRef
Methodological considerations for lipidomic and fungal peptide-based risk stratification in acute liver failure: Letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in a
Hu Fu
Clinical and Molecular Hepatology.2026; 32(3): e283. CrossRef
Metabolomic profiling of Ashwagandha (Withania somnifera): linking bioactive compounds to functional therapeutic roles
Gaurav Tripathi, Vasundhra Bindal, Sanju Yadav, Manisha Yadav, Neha Sharma, Sushmita Pandey, Vipul Sharma, Nupur Sharma, Babu Mathew, Yash Magar, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
Frontiers in Molecular Biosciences.2026;[Epub] CrossRef

11,969 View
315 Download
9 Web of Science
Crossref

Reviews

Liver Transplantation

Prediction and management of small-for-size syndrome in living donor liver transplantation: Jia-hao Law, Alfred Wei-Chieh Kow; Clin Mol Hepatol 2025;31(Suppl):S301-S326.
Published online December 10, 2024; DOI: https://doi.org/10.3350/cmh.2024.0870

Abstract
PDF

Small-for-size syndrome (SFSS) remains a critical challenge in living donor liver transplantation (LDLT), characterized by graft insufficiency due to inadequate liver volume, leading to significant postoperative morbidity and mortality. As the global adoption of LDLT increases, the ability to predict and manage SFSS has become paramount in optimizing recipient outcomes. This review provides a comprehensive examination of the pathophysiology, risk factors, and strategies for managing SFSS across the pre-, intra-, and postoperative phases. The pathophysiology of SFSS has evolved from being solely volume-based to incorporating portal hemodynamics, now recognized as small-for-flow syndrome. Key risk factors include donor-related parameters like age and graft volume, recipient-related factors such as MELD score and portal hypertension, and intraoperative factors related to venous outflow and portal inflow modulation. Current strategies to mitigate SFSS include careful graft selection based on graft-to-recipient weight ratio and liver volumetry, surgical techniques to optimize portal hemodynamics, and novel interventions such as splenic artery ligation and hemiportocaval shunts. Pharmacological agents like somatostatin and terlipressin have also shown promise in modulating portal pressure. Advances in 3D imaging and artificial intelligence-based volumetry further aid in preoperative planning. This review emphasizes the importance of a multifaceted approach to prevent and manage SFSS, advocating for standardized definitions and grading systems. Through an integrated approach to surgical techniques, hemodynamic monitoring, and perioperative management, significant strides can be made in improving the outcomes of LDLT recipients. Further research is necessary to refine these strategies and expand the application of LDLT, especially in challenging cases involving small-for-size grafts.

Citations

Citations to this article as recorded by

Dual, Split and Multi-Graft Liver Transplantation: Surgical Strategies to Maximize Liver Utilization
Josip Basić, Ivan Romić, Juraj Kolak, Goran Pavlek, Hrvoje Silovski
Transplantology.2026; 7(1): 2. CrossRef
Experimental and Clinical Transplantation.2026;[Epub] CrossRef
Liver regeneration: cytokine regulation targeting hepatocytes and beyond
Ting Xiao, Zhangliu Jin, Jiangming Deng, Wen Meng
Life Medicine.2026;[Epub] CrossRef
A scoping review of artificial intelligence in living donor liver transplantation - current status and untapped potential
Karin K. Y. Ho, Albert C. Y. Chan
Artificial Intelligence Surgery.2026; 6(1): 192. CrossRef
Is the 0.80% graft‐to‐recipient weight threshold still relevant in modern adult living donor liver transplantation?
Dimitri A Raptis, Leen Alshibi, Sami A Kareem, Sultan Aljudaibi, Massimo Malago, Dieter C Broering
Hepatobiliary & Pancreatic Diseases International.2026; 25(3): 299. CrossRef
Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival
Ning Wang, Ruiqi Sun, Yang Fu, Zhonghan Wu, Xinyu Tong, Hong Tang, Wentao Zhao, Zhi Liang, Jintao Zheng, Yanan Guan, Ke Zhou, Penghong Song, Shusen Zheng, Hangxiang Wang, Haiyang Xie
Advanced Science.2026;[Epub] CrossRef
Simultaneous Splenic Artery Ligation During Adult Orthotopic Liver Transplantation Improves Surgical Outcomes
Zichen Wang, Zhan Qu, Fan Mu, Lexuan Xu, Liangshuo Hu, Bo Wang, Jianhua Shi
World Journal of Surgery.2025; 49(10): 2909. CrossRef
PORTAL FLOW MODULATION IN LIVING DONOR LIVER TRANSPLANTATION
M Tursynbay, M Doskhanov, Z Ospan, B Baimakhanov, S Kaniyev, S Tileuov, D Mukazhanov, A Chormanov
BULLETIN OF SURGERY OF KAZAKHSTAN.2025; 85(4): 73. CrossRef

13,863 View
368 Download
9 Web of Science
Crossref

Hepatitis E as a trigger for acute-on-chronic liver failure: Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela; Clin Mol Hepatol 2025;31(Suppl):S196-S204.
Published online November 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0758

Abstract
PDF

Acute hepatitis E virus (HEV) infection is typically self-limiting and has a favourable prognosis. However, certain populations such as patients with pre-existing chronic liver disease may experience severe manifestations, including progression to acute-on-chronic liver failure (ACLF). Among viral hepatitis types, hepatitis A, E, and B are major causes of ACLF. Active screening and early diagnosis of HEV infection in patients with cirrhosis, especially those who develop ACLF, can improve management and enable timely antiviral therapy. Preventive measures, including HEV vaccination for high-risk groups, could reduce the morbidity and mortality associated with hepatitis E.

Citations

Citations to this article as recorded by

Virus de la hepatitis E: un problema de salud pública emergente
María Teresa Pérez-Gracia, Lara Martínez-Celdrán, Clara Más-Comes
Medicina Clínica.2026; 166(2): 107286. CrossRef
Shellfish as a Potential Source of Hepatitis E Virus: Epidemiological Evidence, Biological Plausibility, and Research Gaps
Hiroaki Okamoto
Viruses.2026; 18(2): 220. CrossRef
Hepatitis E virus: An emerging public health problem
María Teresa Pérez-Gracia, Lara Martínez-Celdrán, Clara Más-Comes
Medicina Clínica (English Edition).2026; 166(2): 107286. CrossRef
Clinical characteristics of hospitalized patients with hepatitis E virus infection in Poland: a multi-centre retrospective study
Anna Parfieniuk-Kowerda, Jerzy Jaroszewicz, Piotr Grabarczyk, Dorota Zarebska-Michaluk, Katarzyna Sikorska, Anna Piekarska, Aleksandra Berkan-Kawinska, Dorota Kozielewicz, Małgorzata Pawlowska, Monika Pazgan-Simon, Barbara Sobala-Szczygiel, Piotr Zielinsk
Advances in Medical Sciences.2026; 71(1): 75. CrossRef
Global Temporal Trends and Projections of Acute Hepatitis E Epidemiology for Adults 65 Years and Older from 1990 to 2021: Global Burden of Disease 2021 Based Study
Shuangshuang Ma, Qingling Wang, Junjie Lin, Yufeng Gao
Tropical Medicine and Infectious Disease.2026; 11(3): 82. CrossRef
Cholinesterase and the association between hepatic steatosis and liver fibrosis in patients with prior hepatitis E
Ziteng Wang, Zhe Yu, Wen An, Herui Wei, Jing Luo, Mengqi Li, Lingling He, Jiali Ma, Fan Xiao, Lijuan Sun, Qi Gao, Hui Zhong, Hongshan Wei
European Journal of Medical Research.2026;[Epub] CrossRef
Hepatitis E Virus Infection as a Trigger of Hepatic Decompensation: A Single‐Center Prospective and Cross‐Sectional Study From Rosario, Argentina
Julián Acosta, Alceo Galimberti, Fernando Bessone, Hugo Tanno, Daniela Gardiol, María Virginia Reggiardo, Ana Laura Cavatorta
Journal of Medical Virology.2026;[Epub] CrossRef
Nationwide Detection and Molecular Characterization of Hepatitis E Virus RNA in Retail Pork Meat in Japan
Masaharu Takahashi, Manri Kawakami, Yukihiro Sato, Tatsunori Nakano, Jun Inoue, Junichi Koyama, Hitoshi Mizuo, Tomoya Koda, Kazumi Yamasaki, Hiroshi Okano, Akio Miyasaka, Shunji Watanabe, Norio Isoda, Tomofumi Takagi, Shinji Fujiwara, Hiroshi Ohnishi, Put
Viruses.2026; 18(6): 621. CrossRef
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis
Katja Dinkelborg, Christian Niehaus, Birgit Bremer, Christine Wundes, Anja Tiede, Natalie Petruch, Katja Deterding, Anke R. M. Kraft, Björn Hartleben, Markus Cornberg, Heiner Wedemeyer, Patrick Behrendt, Benjamin Maasoumy
Liver International.2026;[Epub] CrossRef
Conjugated bilirubin reduces hepatitis E virus infectivity by modulating immunometabolic processes
Javier Orozco-Cordoba, Julio Y Anaya-Covarrubias, Minerva D Santiago, Diego Zamora, Sonia Roman, Arturo Panduro, Julio César Carrero, Nora A Fierro
Journal of Leukocyte Biology.2026;[Epub] CrossRef
Clinical Guidelines for Hepatitis E Vaccination in India: An Expert Panel Consensus Report on the Recombinant Hepatitis E Vaccine, HEV 239
Mohammad Sultan Khuroo, Naira S. Khuroo
Pathogens.2026; 15(8): 783. CrossRef
Efficacy and safety of mesenchymal stem cell therapy in acute on chronic liver failure: a systematic review and meta-analysis of randomized controlled clinical trials
Wenming Lu, Longxiang Yan, Lulu Peng, Xuesong Wang, Xingkun Tang, Jing Du, Jing Lin, Zhengwei Zou, Lincai Li, Junsong Ye, Lin Zhou
Stem Cell Research & Therapy.2025;[Epub] CrossRef
Hepatitis A and E Viruses Are Important Agents of Acute Severe Hepatitis in Asia: A Narrative Review
Reina Sasaki-Tanaka, Tatsuo Kanda, Takeshi Yokoo, Hiroyuki Abe, Kazunao Hayashi, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai
Pathogens.2025; 14(5): 454. CrossRef
The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure
Xiaojing Qin, Shuang Wang, Zhanyao Yan, Ninghui Zhao, Jia Yao
Frontiers in Microbiology.2025;[Epub] CrossRef
Ribavirina como tratamiento de hepatitis E aguda grave sobre hepatopatía crónica: experiencia clínica
Alba Rabadán Mata, María Dolores Antón Conejero, José María Paredes Arquiola
Medicina Clínica.2025; 165(6): 107187. CrossRef
Ribavirin as a treatment for severe acute hepatitis E on chronic liver disease: Clinical experience
Alba Rabadán Mata, María Dolores Antón Conejero, José María Paredes Arquiola
Medicina Clínica (English Edition).2025; 165(6): 107187. CrossRef

10,676 View
208 Download
14 Web of Science
Crossref

Editorials

Steatotic liver disease

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”: Myeung Gi Choi, Na Young Lee, Ja Hyun Koo; Clin Mol Hepatol 2025;31(2):592-595.
Published online November 6, 2024; DOI: https://doi.org/10.3350/cmh.2024.0971

Citations

Citations to this article as recorded by

JAB1/CRL4B complex represses PPARG/ACSL5 expression to promote breast tumorigenesis
Ting Hu, Tianyu Ma, Miaomiao Huo, Jiaxiang Liu, Die Zhang, Yu Li, Jinyuan Chang, Min Zhang, Yinuo Wang, Tianyang Gao, Baowen Yuan, Siqi Wang, Qing Li, Xiaoqi Ma, Jingyao Zhang, Wei Huang, Yan Wang
Cell Death & Differentiation.2026; 33(6): 1175. CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef

9,050 View
138 Download
3 Web of Science
Crossref

Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis”: Ho Soo Chun, Minjong Lee; Clin Mol Hepatol 2025;31(1):261-263.
Published online September 20, 2024; DOI: https://doi.org/10.3350/cmh.2024.0795

Citations

Citations to this article as recorded by

Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment
Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren
Exploration of Digestive Diseases.2026;[Epub] CrossRef
Optimizing hepatitis C micro-elimination in forensic psychiatric settings: Cost-effectiveness of screening strategies in Korea
Gyeongseon Shin, Sang Hoon Ahn, Hankil Lee, Beom Kyung Kim
Journal of Infection and Public Health.2026; 19(9): 103331. CrossRef
Gut Microbiota Recovery After Direct-Acting Antiviral Therapy for Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Jing-Hong Hu, Ming-Ling Chang, Tung-Jung Huang, Yung-Yu Hsieh, Nai-Jen Liu, Kai-Feng Sung, Jui-Hsiang Tang
Microorganisms.2026; 14(8): 1843. CrossRef

9,398 View
68 Download
2 Web of Science
Crossref

Correspondence

Steatotic liver disease

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”: Baokai Sun, Likun Zhuang; Clin Mol Hepatol 2025;31(1):e67-e69.
Published online September 10, 2024; DOI: https://doi.org/10.3350/cmh.2024.0744

6,037 View
97 Download

Original Articles

Steatotic liver disease

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD: Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang; Clin Mol Hepatol 2024;30(4):863-882.
Published online July 26, 2024; DOI: https://doi.org/10.3350/cmh.2024.0268

Backgrounds/Aims
Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood.
Methods
The Tm6sf2^167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2^167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC).
Results
The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFD-induced Tm6sf2^167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice.
Conclusions
The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.

Citations

Citations to this article as recorded by

Association of Circadian Rhythms With the Risk of Chronic Liver Disease: Findings From a Large Prospective Study
Rong Yang, Can Shen, Yu Jia, Yi Yao, Yiheng Zhou, Yu Cheng, Yonglang Cheng, Rui Zeng, Zhi Wan, Qian Zhao, Dongze Li, Xiaoyang Liao
Clinical and Translational Gastroenterology.2026; 17(1): e00949. CrossRef
High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health
Hong-Yuan Yin, Qian-Hui You, Wei-Jie Zhang, Guang Ji, Yan-Qi Dang
World Journal of Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models
Jack Leslie, Kishore A. Krishnamurthy, Indresh K. Gopalsamy, Patricia Inacio, Meritxell Huch, Suchira Gallage, Fiona Oakley, Michele Vacca
Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 286. CrossRef
1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3
Tianyang Jin, Yanni Zhao, Tingxin Xu, Yi Fang, Yaqian Cui, Wenqi Liu, Yongqiang Xiong, Jiaxi Ye, Wu Luo, Bo Hong, Guang Liang, Xiang Hu, Lijiang Huang, Yi Wang
International Immunopharmacology.2026; 174: 116351. CrossRef
Competing Cardiometabolic Pathways of Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease
Masashi Hirooka, Teruki Miyake, Ryo Yano, Yoshiko Nakamura, Yuki Okazaki, Toyoki Shimamoto, Atsushi Yukimoto, Yasunori Yamamoto, Takao Watanabe, Osamu Yoshida, Kana Hirooka, Yoshio Tokumoto, Masanori Abe, Takeru Iwata, Yoichi Hiasa
Gastro Hep Advances.2026; 5(4): 100882. CrossRef
Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis
Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang
BMJ Open Gastroenterology.2026; 13(1): e002123. CrossRef
Lipid metabolism-MAFLD crosstalk: mechanisms and therapy
Bojia Li, Shengai Piao, Yin Fu, Qiang Fu, Peiyao Qin, Weitai Kong, Yidi Ma, Zhe Zhang, Xue Fang, Xiaoyang Hu
Frontiers in Endocrinology.2026;[Epub] CrossRef
Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province
Shuo Zhou, Daya Zhang, Runyu Chen, Yan-ting Lv, Da Li, Xianfeng Huang, Fengjiao Mao, Shimei Huang, Shiju Chen, Chen Chen, Ying Mo, Yiping Du, Yuliang Huang, Fan Zeng, Qicen Yao, Feihu Bai
Scientific Reports.2026;[Epub] CrossRef
Selenium Protects Against Cadmium-Induced Hepatotoxicity via Regulation of Lipid Metabolism and Inflammatory Pathways
Zilong Wu, Xinyi Chen, Xiaoying Pan, Kai Luo, Zixiong Zhang, Changyu Zhou, Haibo Wang, Chuying Huang
Frontiers in Bioscience-Landmark.2026;[Epub] CrossRef
Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review
Aleksandra Klisic, Ratko Tomašević, Slavko Djuraskovic, Filiz Mercantepe, Ana Ninic
Archives of Medical Science.2026;[Epub] CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim
Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Microbial metabolites contribute to the pathogenesis of metabolic dysfunction-associated fatty liver disease in high-fat diet-fed mice
Kai-Wen Cai, Zhen-Chuan Lin, Xue-Mei Zhang, Jia-Yun Yu, Tian-jiao Cui, Yi-Qing Zhang, Rong-Hua Zou, Zhi-Hua Zheng, Yao-Liang Zhou, Ting Zhu, Yong-Ping Lu
Microbial Pathogenesis.2026; 218: 108634. CrossRef
Genetics and epigenetics in tumor necrosis factor-alpha (TNF-α) and transmembrane 6 superfamily member 2 (TM6SF2) in alcohol induced liver cirrhosis
Bhagyalakshmi Shankarappa, Jayant Mahadevan, Pratima Murthy, Biju Viswanath, Harshad Devarbhavi, Sanjeev Jain, Meera Purushottam
Frontiers in Medicine.2026;[Epub] CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Andrea Caddeo, Rosellina M. Mancina
Clinical and Molecular Hepatology.2025; 31(1): 293. CrossRef
Causal roles of immune cells and metabolites in chronic pancreatitis: a mendelian randomization study
Chao Zhang, Tao Yang, Yuan Yu, Qian Jia, Wan-Meng Xiao, Sha Liu, Ze-Hui Yu, Cheng-Li Wen, Yan Wei, Hao Li, Mu-Han Lü
Hereditas.2025;[Epub] CrossRef
Effects of polyphenols on non-alcoholic fatty liver disease: a case study of resveratrol
Ying Zhao, Jiali Ren, Weisan Chen, Xinchen Gao, Hongjian Yu, Xiankuan Li, Yanchao Zheng, Jinlong Yang
Food & Function.2025; 16(8): 2926. CrossRef
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina
American Journal of Physiology-Cell Physiology.2025; 328(5): C1637. CrossRef
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement
Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(10): 13647. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years
Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim
Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef

10,034 View
388 Download
22 Web of Science
Crossref

Viral hepatitis

Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis: Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi; Clin Mol Hepatol 2024;30(Suppl):S106-S116.
Published online July 23, 2024; DOI: https://doi.org/10.3350/cmh.2024.0371

Backgrounds/Aims
Accurate diagnosis of significant liver fibrosis in patients with chronic hepatitis B (CHB) is crucial when determining whether to initiate antiviral treatment (AVT). We conduct a meta-analysis to assess the diagnostic performance of vibration-controlled transient elastography (VCTE) for significant liver fibrosis in AVT-naïve CHB patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal (ULN).
Methods
The Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases were searched to identify studies that compared the performance of VCTE and liver biopsy (reference standard) when diagnosing significant liver fibrosis (≥F2) in AVT-naïve CHB patients with ALT within 5-fold the ULN. A hierarchical summary receiver operating characteristic curve (HSROC) and bivariate model were performed to evaluate the diagnostic performance of VCTE in the meta-analysis.
Results
Eight studies (2,003 patients) were included. The summary sensitivity and specificity for diagnosis of significant liver fibrosis were 0.78 (95% confidence interval [CI], 0.66–0.86) and 0.72 (95% CI, 0.60–0.82), respectively. The HSROC for the diagnosis of significant liver fibrosis was 0.81 (95% CI, 0.72–0.86). The optimal cutoff value of VCTE for diagnosis of significant liver fibrosis was 7.7 kPa with a sensitivity of 0.64 (95% CI, 0.50–0.76) and specificity of 0.83 (95% CI, 0.72–0.90).
Conclusions
Our study demonstrated that VCTE has an acceptable diagnostic performance for significant liver fibrosis in AVT-naïve CHB patients with ALT within 5-fold the ULN.

Citations

Citations to this article as recorded by

Chronic Hepatitis B Infection: Patient Guidance
Lung‐Yi Mak, Jimmy Che‐To Lai, Ken Liu, Rashid Lui, Sakkarin Chirapongsathorn, Kuo Chao Yew, Mara Teresa Panlilio, Cosmas Rinaldi Adithya Lesmana, Ruveena Bhavani Rajaram, Liang Shen, Desmond Cheung, Lung‐Fai Wong, Hye Won Lee, Madhumita Premkumar, Anand
Journal of Gastroenterology and Hepatology.2026; 41(1): 61. CrossRef
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update
Hong You, Rakhi Maiwall, Jing Chen, Sang Hoon Ahn, Kadir Dokmeci, Xiaoguang Dou, Manal El-Sayed, Jian-Gao Fan, Rino Gani, Zhiliang Gao, Jacob George, Hasmik Ghazinian, George Goh, Saeed Hamid, Jinlin Hou, Shang-Chin Huang, Dong Ji, Jidong Jia, Tatsuo Kand
Hepatology International.2026; 20(4): 911. CrossRef
The Use of Ultrasound-Based Elastography Techniques in Liver Fibrosis: A Narrative Review
Arjuna Priyadarsin De Silva, Shashini Madushika Hathurusinghe, Madunil Anuk Niriella, Hithunadura Janaka De Silva
Diagnostics.2026; 16(17): 2694. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk
Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim
Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
Health Science Reports.2025;[Epub] CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
Deniz Borcak, Zuhal Yesilbag, Yusuf Emre Ozdemir, Adile Sevde Demir, Esra Salim Dogdas, Aysegul Inci Sezen, Esra Canbolat Unlu, Sevtap Senoglu, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar
Journal of Clinical Medicine.2025; 14(22): 8164. CrossRef
Vibration-Controlled Transient Elastography in Chronic Liver Disease: Current Research Insights
Ho Soo Chun
Clinical Ultrasound.2025; 10(2): 69. CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
Jung Hwan Yu
The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
Mi Na Kim
The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
Han Ah Lee
Clinical Ultrasound.2024; 9(2): 70. CrossRef

8,068 View
153 Download
7 Web of Science
Crossref

Correspondence

Acute liver injury and Acute liver failure

Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”: Do Seon Song, Dong Joon Kim; Clin Mol Hepatol 2024;30(4):1012-1015.
Published online June 18, 2024; DOI: https://doi.org/10.3350/cmh.2024.0448

6,429 View
29 Download

Editorial

Acute liver injury and Acute liver failure

Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”: Simone Incicco, Salvatore Piano; Clin Mol Hepatol 2024;30(4):695-697.
Published online June 3, 2024; DOI: https://doi.org/10.3350/cmh.2024.0409

Citations

Citations to this article as recorded by

Dynamic CD177/CD10 ratio for infection diagnosis and mortality risk stratification in critically ill patients: a prospective cohort study
Jiamin Huang, Keliang Xie, Heyue Li, Xiao Wen, Yiwen Mei, Jiahui Chen, Aixiang Yang, Bingwei Sun
eBioMedicine.2026; 123: 106100. CrossRef
Sepsis: Heterogeneity, Immunopathology, and Advances in Therapeutic Strategies
Junxing Qu, Peizhi Li, Zhiheng Sun
The FASEB Journal.2026;[Epub] CrossRef
RAC1 as a novel therapeutic target for acute liver failure
Barbara Bueloni, Esteban Fiore, María José Cantero, Lucia Lameroli, Catalina Atorrasagasti, Matías Ciarlantini, Andrea Barquero, Lucía Gandolfi Donadio, Daiana Ganiewich, Francisco Orozco, Martín Fauda, Julieta Comin, Ali Canbay, Juan Bayo, Guillermo Mazz
JHEP Reports.2025; 7(11): 101547. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
Do Seon Song, Dong Joon Kim
Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef

7,321 View
46 Download
4 Web of Science
Crossref

Correspondence

Hepatic neoplasm

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”: Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim; Clin Mol Hepatol 2024;30(4):1005-1008.
Published online May 30, 2024; DOI: https://doi.org/10.3350/cmh.2024.0394

Citations

Citations to this article as recorded by

Multiple drugs

Reactions Weekly.2025; 2068(1): 279. CrossRef

5,747 View
77 Download
Crossref

Original Article

Acute liver injury and Acute liver failure

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment: Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party; Clin Mol Hepatol 2024;30(3):388-405.
Published online April 11, 2024; DOI: https://doi.org/10.3350/cmh.2023.0563

Background/Aims
Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified qSOFA (m-qSOFA) to identify high-risk patients among those with acutely deteriorated chronic liver disease (CLD), especially those with acute-onchronic liver failure (ACLF).
Methods
We used data from both the Korean Acute-on-Chronic Liver Failure (KACLiF) and the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) cohorts. qSOFA was modified by replacing the Glasgow Coma Scale with hepatic encephalopathy, and an m-qSOFA ≥2 was considered high.
Results
Patients with high m-qSOFA had a significantly lower 1-month transplant-free survival (TFS) in both cohorts and higher organ failure development in KACLiF than those with low m-qSOFA (Ps<0.05). Subgroup analysis by ACLF showed that patients with high m-qSOFA had lower TFS than those with low m-qSOFA. m-qSOFA was an independent prognostic factor (hazard ratios, HR=2.604, 95% confidence interval, CI 1.353–5.013, P=0.004 in KACLiF and HR=1.904, 95% CI 1.484– 2.442, P<0.001 in AARC). The patients with low m-qSOFA at baseline but high m-qSOFA on day 7 had a significantly lower 1-month TFS than those with high m-qSOFA at baseline but low m-qSOFA on day 7 (52.6% vs. 89.4%, P<0.001 in KACLiF and 26.9% vs. 61.5%, P<0.001 in AARC).
Conclusions
Baseline and dynamic changes in m-qSOFA may identify patients with a high risk of developing organ failure and short-term mortality among CLD patients with acute deterioration.

Citations

Citations to this article as recorded by

Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
S. K. Sarin, Ashok Choudhury, Anupam Kumar, Nadim Mahmud, G. H. Lee, Qin Ning, Soek-Siam Tan, Kessarin Thanapirom, Vinod Arora, Nobuaki Nakayama, Jun Li, Constantine J. Karvellas
Nature Reviews Gastroenterology & Hepatology.2026; 23(5): 411. CrossRef
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
Journal of Korean Medical Science.2026;[Epub] CrossRef
Shear Wave Elastography Combined with ALBI Score Enhances Prediction of Hepatic Decompensation in Chronic Liver Disease
Jaejun Lee, Hyun Yang, Si Hyun Bae, Sun Hong Yoo, Soon Woo Nam, Jiwoon Yoon, Jung Hyun Kwon, Soon Kyu Lee
JHEP Reports.2026; : 101963. CrossRef
Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy
Hankil Lee, Sang Hoon Ahn, Beom Kyung Kim
Yonsei Medical Journal.2025; 66(11): 713. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
Do Seon Song, Dong Joon Kim
Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure a
Simone Incicco, Salvatore Piano
Clinical and Molecular Hepatology.2024; 30(4): 695. CrossRef
Revisiting septic shock in cirrhosis: a call for personalized management
Vishnu Girish, Rakhi Maiwall
Expert Review of Gastroenterology & Hepatology.2024; 18(12): 795. CrossRef

10,400 View
149 Download
11 Web of Science
Crossref

Correspondence

Viral hepatitis

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”: Ming-Ying Lu, Ming-Lung Yu; Clin Mol Hepatol 2024;30(2):274-275.
Published online March 5, 2024; DOI: https://doi.org/10.3350/cmh.2024.0152

Citations

Citations to this article as recorded by

Prevalence and Modes of Transmission of Hepatitis C Virus Infection: A Historical Worldwide Review
Tommaso Stroffolini, Giacomo Stroffolini
Viruses.2024; 16(7): 1115. CrossRef
The role of artificial intelligence in the management of liver diseases
Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef

7,333 View
52 Download
2 Web of Science
Crossref

Editorial

Viral hepatitis

Toward hepatitis C virus elimination using artificial intelligence: Moon Haeng Hur, Jeong-Hoon Lee; Clin Mol Hepatol 2024;30(2):147-149.
Published online February 23, 2024; DOI: https://doi.org/10.3350/cmh.2024.0135

Citations

Citations to this article as recorded by

Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef
Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions
Kirolos Eskandar
iLIVER.2025; 4(4): 100205. CrossRef
Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
Ming-Ying Lu, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 274. CrossRef

7,748 View
118 Download
3 Web of Science
Crossref

Letter to the Editor

Artificial intelligence, epidemiology, methodology, or others

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”: Hinpetch Daungsupawong, Viroj Wiwanitkit; Clin Mol Hepatol 2024;30(1):111-112.
Published online October 13, 2023; DOI: https://doi.org/10.3350/cmh.2023.0394

8,143 View
81 Download

Review

Steatotic liver disease

Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases: Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Jia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu; Clin Mol Hepatol 2024;30(1):16-36.
Published online October 4, 2023; DOI: https://doi.org/10.3350/cmh.2023.0315

Abstract
PDF

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD.

Citations

Citations to this article as recorded by

FIB‐4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD
Ya‐Chin Huang, Chih‐Wen Wang, Jiun‐Chi Huang, Po‐Cheng Liang, Ming‐Lun Yeh, Yi‐Yu Chen, Yi‐Hung Lin, Tyng‐Yuan Jang, Yu‐Ju Wei, Ming‐Yen Hsieh, Chao‐Kuan Huang, Hsu‐Han Chien, Chia‐Jen Wu, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Chia‐I Lin, Chung‐Fen
Journal of Gastroenterology and Hepatology.2026; 41(1): 332. CrossRef
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
Alimentary Pharmacology & Therapeutics.2026; 63(8): 1119. CrossRef
Serum mir-181a as a potential serological biomarker for metabolic dysfunction-associated fatty liver disease: A cross sectional study
Ke-Gong Xiong, Jin-Feng Kong, Tai-Shun Lin, Qing-Biao Lin, Kun-Yu Ke
Medicine.2026; 105(4): e47290. CrossRef
Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease
Chieh Liu, Yi-Fen Shih, Chun-Jen Liu
Clinical and Molecular Hepatology.2026; 32(2): 565. CrossRef
Metabolic biomarkers predict subclinical cardiac remodeling in obese individuals
Mengjie Hu, Huawei Wang, Zixuan Mei, Cheng Gong, Lan Lan, Zixuan Ma, Binhao Zhang, Haomiao Fan, Yuqing Zhang, He Wang, Wanshun Chun, Dingyu Pan, Jianliang Zhou, Zhen Li
Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis
Hao-Chien Hung, Po-Jung Hsu, Yin Lai, Wei-Chen Lee, Chen-Fang Lee
Annals of Hepatology.2026; 31(2): 102231. CrossRef
Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Jee‐Fu Huang, Chi‐Yi Chen, Ming‐Jong Bair, Tzu‐Chun Lin, Ming‐Lun Yeh, Pei‐Chien Tsai, Yu‐Ju Wei, Chih‐Wen Wang, Po‐Chen Liang, Ming‐Yen Hsieh, Mei‐Hsuan Lee, Chia‐Yen Dai, Chung‐Feng Huang, Ming‐Lung Yu, Wan‐Long Chuang
The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
MRI of Hepatocellular Carcinoma: Cross-regional Perspectives on Trends and Opportunities
Cher Heng Tan, Hanyu Jiang, Yuan-Cheng Wang, Hsien Min Low, Christopher Welle, Shuwei Zhou, Giuseppe Brancatelli, Sudhakar Venkatesh, Jeong Min Lee
RadioGraphics.2026;[Epub] CrossRef
A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B
Moon Haeng Hur, Terry Cheuk-Fung Yip, Seung Up Kim, Hyun Woong Lee, Han Ah Lee, Hyung-Chul Lee, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Hwi Young Kim, Yeon Seok Seo, Hyunjae Shin, Jeayeon Park, Yunmi Ko, Yo
Journal of Hepatology.2025; 82(2): 235. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?”
Moon Haeng Hur, Jeong-Hoon Lee
Journal of Hepatology.2025; 82(3): e143. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure
Kai-Chun Chang, Tung-Hung Su, Cho-Kai Wu, Shang-Chin Huang, Tai-Chung Tseng, Chun-Ming Hong, Shih-Jer Hsu, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
European Journal of Heart Failure.2025; 27(3): 512. CrossRef
Metabolic dysfunction-associated steatotic liver disease and its associated health risks
Xia-Rong Liu, Szu-Ching Yin, Yi-Ting Chen, Mei-Hsuan Lee
Journal of the Chinese Medical Association.2025; 88(5): 343. CrossRef
Fatty Liver and Hyperuricemia in Workers: Combined Effects on Metabolic Dysfunction and the Role of Lifestyle Factors
Jui-Hua Huang, Ren-Hau Li, Hon-Ke Sia, Feng-Cheng Tang
Metabolites.2025; 15(5): 318. CrossRef
Application of insulin resistance score in type 2 diabetes mellitus complicated with fatty liver and liver fibrosis
Shaojie Duan, Mengdie Chen, Jie Chen, Yaojian Shao, Xiaolong Jin, Chaohui Wang, Ping Feng, Xiaosheng Teng, Zhenjun Yu
European Journal of Gastroenterology & Hepatology.2025; 37(10): 1155. CrossRef
The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation
Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace
Biomedicine & Pharmacotherapy.2025; 190: 118375. CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
MAFLD: from a disease framework to patient care
Mohammed Eslam, Jacob George
Hepatology International.2024; 18(S2): 823. CrossRef
Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus
Wei-Fan Hsu
American Journal of Cancer Research.2024; 14(4): 1914. CrossRef
The unfolded features on the synchronized fashion of gut microbiota and Drynaria rhizome against obesity via integrated pharmacology
Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Dong Joon Kim, Ki-Tae Suk
Food Chemistry.2024; 460: 140616. CrossRef
High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang
Scientific Reports.2024;[Epub] CrossRef
MASLD: an emerging factor in the pathophysiology and clinical management of ICC
Zong-Long Li, Jia-Lu Chen, Yue Tang, De-Long Qin, Zhao-Hui Tang
Hepatoma Research.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology
Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng
Cardiology Plus.2024; 9(4): 275. CrossRef

15,516 View
400 Download
28 Web of Science
Crossref

Letter to the Editor

Artificial intelligence, epidemiology, methodology, or others

Letter regarding “Evidence-based hyponatremia management in liver disease”: Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos; Clin Mol Hepatol 2023;29(4):1043-1045.
Published online July 5, 2023; DOI: https://doi.org/10.3350/cmh.2023.0204

Citations

Citations to this article as recorded by

Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clinical and Molecular Hepatology.2023; 29(4): 1048. CrossRef

8,203 View
43 Download
Crossref

Editorial

Hepatic neoplasm

Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan: San-Chi Chen; Clin Mol Hepatol 2023;29(2):352-354.
Published online March 20, 2023; DOI: https://doi.org/10.3350/cmh.2023.0101

Citations

Citations to this article as recorded by

Factors Influencing Overall Survival Period of Stage IV Cancer Patients
Wen Pei Chang, Yen Kuang Lin, Shashank Kaushik
European Journal of Cancer Care.2025;[Epub] CrossRef

8,842 View
78 Download
1 Web of Science
Crossref

Review

Acute liver injury and Acute liver failure

Acute-on-chronic liver failure: Terminology, mechanisms and management: Vinay Kumar BR, Shiv Kumar Sarin; Clin Mol Hepatol 2023;29(3):670-689.
Published online March 20, 2023; DOI: https://doi.org/10.3350/cmh.2022.0103

Abstract
PDF

Acute-on-chronic liver failure is an acute deterioration of liver function manifesting as jaundice and coagulopathy with the development of ascites, with a high probability of extrahepatic organ involvement and high 28-day mortality. The pathogenesis involves extensive hepatic necrosis, which is associated with severe systemic inflammation and subsequently causes the cytokine storm, leading to portal hypertension, organ dysfunction, and organ failure. These patients have increased gut permeability, releasing lipopolysaccharide (LPS) and damage-associated molecular patterns (DAMPS) in the blood, leading to hyper-immune activation and the secretion of cytokines, followed by immune paralysis, causing the development of infections and organ failure in a proportion of patients. Early detection and the institution of treatment, especially in the "Golden Window" period of 7 days, gives an opportunity for reversal of the syndrome. Scores like the Asian Pacific Association for the Study of the Liver (APASL) ACLF research consortium (AARC) score, a model for end stage liver disease (MELD), and the CLIF Consortium acute-on-chronic liver failure (CLIF-C ACLF) score can help in the prediction of mortality. Treatment strategy includes treatment of acute insult. Patients should be considered for early transplant with MELD score >28, AARC score >10, high-grade hepatic encephalopathy, and in the absence of >2 organ failure or overt sepsis to improve survival of up to 80% at five years. Patients, with no option of transplant, can be treated with emerging therapies like faecal microbial transplant, plasma exchange, etc., which need further evaluation.

Citations

Citations to this article as recorded by

Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure
Xia Yu, Weihong Tian, Xuanwen Bao, Zhiwei Li, Huilan Tu, Xianbin Xu, Jiyang Chen, Quan Zhang, Jianing Chen, Chuan Liu, Xiaomeng Dai, Xinyi Xu, Haoda Weng, Yue Yu, Xiuding Zhang, Ruoqi Zhou, Wenfeng Zhu, Yan Lan, Jinlin Cheng, Min Xu, Wei Wu, Rui Huang, Yi
Hepatology.2026; 83(5): 1174. CrossRef
A cationic thermosensitive polymer scaffold combined with fibroblast growth factor- 4/insulin-like growth factor-1 (FGF-4/IGF-1) promotes liver regeneration in acute liver failure
Beining Liao, Qingpeng Liu, Dandan Zhang, Guowei Huang, Kuo Ma, Shengjun Pan, Jingfeng Che, Yan-Qing Guan
Colloids and Surfaces B: Biointerfaces.2026; 257: 115171. CrossRef
Single-cell analysis identifies RETN + monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure
Xianbin Xu, Jiyang Chen, Xia Yu, Zhiwei Li, Jianing Chen, Danfeng Fang, Xingchen Lin, Huilan Tu, Xinyi Xu, Sisi Yang, Jinlin Cheng, Kai Gong, Haoda Weng, Yue Yu, Xiuding Zhang, Yan Lan, Biao Li, Guoqiang Cao, Hai Chen, Leiming Chen, Xiaohan Qian, Wenzheng
Gut.2026; 75(3): 605. CrossRef
Novel insights into cyanobacterial (microcystins) neurotoxicity in rats: hepatic encephalopathy
Wen-Li Xu, Liang Chen, Hui-Hui Fan, Geoffrey A. Codd, John P. Giesy, Yu-Ming Guo, Elizabeth D. Hilborn, Daniela Sedan, Darío Andrinolo, Saurabh Chatterjee, Hai-Jun Wang, Ying Liu, Qian-Hui Wu, Jun He, Shi-Ming Dai, Lin-Lin Xu, Shi-Man Xiao, Yi-Qing Liu, R
Archives of Toxicology.2026; 100(2): 737. CrossRef
Insulin-activated β-cell-liver axis protects against acetaminophen-induced acute liver injury by suppressing oxidative stress and purine catabolism
Yan Zhang, Kerong Liu, Ting Fu, Yuexin Zhang, Bin Xue, Meng Wu, Daheng Yang, Hongbing Chen
Free Radical Biology and Medicine.2026; 244: 166. CrossRef
Current updates in perioperative care for patients with chronic liver disease
Mayura Thilanka Iddagoda, Sherman Picardo, Leon Flicker
Anesthesiology and Perioperative Science.2026;[Epub] CrossRef
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
Journal of Korean Medical Science.2026;[Epub] CrossRef
Early risk stratification of sepsis-related liver injury via machine learning: a multicohort study
Xin Chen, Pinwen Zhou, Jiaqi Wang, Li Zhang, Tingbin Xie, Wei Ma, Xinying Wang
Frontiers in Medicine.2026;[Epub] CrossRef
Comparison of Two Artificial Liver Treatments for Acute Liver Failure: A Retrospective Observational Study
Xiulian Wu, Dongxia Wu, Xiaoqing Sun, Wenhui Wang, Jiayuan Wei, Xin Liu, Yanmei Gu
Nursing in Critical Care.2026;[Epub] CrossRef
A Nomogram Incorporating Sarcopenia and Nutritional Indicators for Mortality Prediction in HBV-Related Acute-Chronic Liver Failure
Jiao Yuan, Wenting Peng, Chuan Jiang, Hui Liu, Shuo Wang, Ying Jiang, Bin Tan, Lei Fu, Shifang Peng
Healthcare.2026; 14(4): 447. CrossRef
The pivotal role of mitochondria in the pathogenesis and treatment of liver failure: a comprehensive review
Qing Peng, Liyuan Hao, Shenghao Li, Fei Yu, Na Li, Xinyu Luo, Jiayun Yue, Qianlan Luo, Kangning Zheng, Xiaoyu Hu
Molecular and Cellular Biochemistry.2026; 481(5): 1895. CrossRef
Cross-species hepatic transcriptomics identify conserved immune-metabolic reprogramming in acute-on-chronic liver failure progression
Panyu Chen, Yun Song, Xiao Lin, Zhaokai Zeng, Wenxi Su, Yunyun Ren, Chen Wang, Kang He, Min Shi, Yugang Wang
Frontiers in Immunology.2026;[Epub] CrossRef
Methyl-CpG-binding domain protein 2 epigenetically represses monocyte HLA-DR expression and promotes immune paralysis in HBV-related acute-on-chronic liver failure
Xiaoqin Liu, Xuhua Jiang, Xueyun Zhang, Qiankun Hu, Xueping Yu, Jian Sun, Mingqin Lu, Jiming Zhang, Yuxian Huang
Frontiers in Immunology.2026;[Epub] CrossRef
Liver regeneration: cytokine regulation targeting hepatocytes and beyond
Ting Xiao, Zhangliu Jin, Jiangming Deng, Wen Meng
Life Medicine.2026;[Epub] CrossRef
Acute-on-chronic liver failure: From definition to pathogenesis and therapy
Yifan Xu, Jingting Liu, Dabao Shang, Robim M Rodrigues, Yu Chen, Xiaogang Xiang
Chinese Medical Journal.2026; 139(8): 1110. CrossRef
Association of ACAG with short-term mortality in liver failure patients: a retrospective analysis based on the MIMIC-IV database
Hang Wang, Shuangli Li, Shunhao Lai, Yunjian Sheng
Scientific Reports.2026;[Epub] CrossRef
Uncovering potentially targetable genes in liver fibrosis via bioinformatics and experimental validation
Hang Li, Deji Xie, Qinghui Wu, Lijia Zhao, Lingshan Yang, Shuya Zheng, Erdong Shen, Yuling Zhou
Scientific Reports.2026;[Epub] CrossRef
Development and validation of a dynamic prognostic score for hepatitis B virus–related acute-on-chronic liver failure
Jiemenglu Li, Jian Yang, Chunyan Jiang, Qingting Zhao, Yufeng Gao, Jiang Li
Journal of International Medical Research.2026;[Epub] CrossRef
Distinct amino acid metabolic subtypes predict prognosis and stratify treatment response in acute-on-chronic liver failure: a multicenter prospective study
Haocheng Zheng, Simiao Yu, Ting Zhou, Shuangnan Fu, Jingjing Zhang, Ning Zhang, Yijiang Liu, Yanyang Huang, Zhaoyun He, Jin Zhang, Pengcheng Liu, Man Gong, Chao Zhou
Hepatology International.2026; 20(3): 864. CrossRef
Current progress in the pathophysiology and potential therapeutic targets of acute-on-chronic liver failure through multiomics approaches
Yingying Yu, Mengyao Li, Yunbo Xie, Fu-sheng Wang, Ming Shi
Infectious Diseases & Immunity.2026;[Epub] CrossRef
Immune microenvironment dynamics in pregnant patients with concomitant autoimmune diseases: mechanisms, challenges, and clinical significance
Zi-Jun Ma, Jun Chen, Chen-Xi Yang, Shun-Ping Lin, Quan Gong, Zachary Braunstein, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong
Military Medical Research.2026; 13(1): 100015. CrossRef
A Systemic Inflammation Response Index (SIRI)-based nomogram for predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure: a retrospective cohort study
Xuwei Wu, Miaomiao Huo, Zechang Chen, Qiaorong Gan, Aifang Lin, Xiuhui Wang, Zuxiong Huang, Qi Zheng
BMC Gastroenterology.2026;[Epub] CrossRef
Polydopamine-mediated EGCG-modified polystyrene microspheres for the synergistic removal of inflammatory cytokines TNF-α and bilirubin in liver failure
Yunzheng Du, Zhuang Liu, Yamin Chai, Biao Wang, Lichun Wang, Zimeng Wang, Xiaofang Guo, Guanlun Zhou, Jingxuan Yang, Chunling Zhu, Leilei Yang, Xinyao Lv, Lailiang Ou
Regenerative Biomaterials.2026;[Epub] CrossRef
Risk factors for pneumonia, hepatic encephalopathy, and acute kidney injury in patients with hepatitis B virus–related acute-on-chronic liver failure
Li Wei, Wenjuan Shi, Xuefang Yang, Haiwen Ma, Hong Wan, Xiaoli Zhou
Frontiers in Medicine.2026;[Epub] CrossRef
Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases
Chuyang Meng, Min Liu, Qianqian Qi, Lixue Cao, Qi Lei, Xifu Liu, Meng Wang
International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
Transplantation of Autologous Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Decompensated Liver Cirrhosis: A Real-World Evidence Study in a Population-Based Cohort
Seul Ki Han, Sung Hwa Kim, Sang Baek Koh, Moon Young Kim
Gut and Liver.2026; 20(3): 452. CrossRef
Trends and disparities in liver failure-related mortality in adults with mental and behavioral disorders due to tobacco use: A retrospective analysis
Sarim Hassan Shahab, Zuha Maryam, Syeda Malika Naqvi, Muhammad Ahmed, Alisha Matloob, Hadia Ghazala Masood, Esha Umair, Muddassir Khalid, Muhammad Talha, Ubaid Ur Rehman
Medicine.2026; 105(20): e48719. CrossRef
Multi‐Omics Identified Factor V Leiden as a Novel Predictor of 90‐Day Mortality in Artificial Liver‐Supported ACLF: A Translational Study
Wen Zhao, Hejing Ruan, Longcan Li, Yan Qiao, Qianqian Wang, Yucun Dong, Yi Luo, Fanghong Liu, Chuanmiao Liu, Jiufa Zhao, Dongdong Li
The FASEB Journal.2026;[Epub] CrossRef
Transfer RNA-derived small RNA-Gly activates the ACPH/GRHL1 axis to facilitate liver cell regeneration in acute-on chronic liver failure
Mingxue Yu, Wenli Xu, Guanzi Chen, Yucheng Lei, Hang Si, Jiayu Liu, Ning Wen, Yutian Chong, Yusheng Jie, Qiyi Zhao
Science China Life Sciences.2026;[Epub] CrossRef
Altered Properties of Bone Marrow-Derived Mesenchymal Stem Cells Exposed to Serum from Patients with Acute-On-Chronic Liver Failure
Wenxin Zhang, Shurong Liu, Zhiru Wang, Chang Sun, Baikun Liu, Lei Zhang
International Journal of Stem Cells.2026; 19(2): 224. CrossRef
Gut microbiota reconstruction after liver transplantation and its association with early postoperative infections in patients with liver failure
Bing Chen, Jun Chen, Zhangpeng Feng, Hanbei Lv, Qinghong Lin, Guoping Jiang
Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Low‐Volume Plasma Exchange Following Double Plasma Molecular Adsorption System in Acute‐On‐Chronic Liver Failure: A Plasma‐Sparing Strategy
Xujia Chen, Linna Yu, Yun Huang, Lifang Zhou, Feng Zhang, Rui Ding, Ying Yao, Rong Qin, Hui Wang
Journal of Clinical Apheresis.2026;[Epub] CrossRef
Infections and Antimicrobial Management in Patients With Acute Liver Failure
Luca Cremascoli, Mattia Puppo, Silvia Martini, Antonio Toscano, Alessandro Girombelli, Francesco Saglietti, Antonio Voza, Christian Zanza, Yaroslava Longhitano
Journal of Intensive Care Medicine.2026;[Epub] CrossRef
The medicinal effect of ulinastatin in various liver diseases
Jia Li, LiJun Hou, Jie Zhang, Chao Sun
Hepatobiliary Communications.2026; 1(1): 100002. CrossRef
Alcohol and high-fat diet aggravate colitis-induced liver injury via glucocorticoid/IL-6-SAA1 axis in mice
Mingrui Zhao, Han Li, Xinghua Gao, Huijuan Da, Xun Cui, Dongquan Jing, Qixiang Zhao, Ying Wang, Yanling Guo, Zhenhua Gao, Shentian Zhuang, Qiuhua Cao
Food and Chemical Toxicology.2026; 216: 116244. CrossRef
Clinical value and safety of liver biopsy in patients with liver failure
Jingran Jiao, Rui Zhao, Yongping Zhang, Manman Xu, Yu Chen
BMC Gastroenterology.2026;[Epub] CrossRef
Efficacy and safety of double plasma molecular adsorption system combined with plasma exchange for acute-on-chronic liver failure: updated systematic review and meta-analysis of randomized controlled trials
Lizhen Chen, Xin Meng, Caili Sun, Yongning Xin
European Journal of Medical Research.2026;[Epub] CrossRef
Development and validation of a novel prognostic score for HBV-related acute-on-chronic liver failure
Qian Song, Lin Lv, Chuanfei Li, Zhechuan Mei, Shengtao Liao
Frontiers in Medicine.2026;[Epub] CrossRef
Does Acute-on-Chronic Liver Failure Still Matter After Liver Transplantation? A Systematic Review and Meta-Analysis of One-Year Survival
Ethar Yousif, Jonathan Soldera
Diagnostics.2026; 16(14): 2206. CrossRef
Monocyte-to-Platelet Ratio Shows Modestly Improved Discrimination Over Model for End-Stage Liver Disease (MELD) 3.0 in Predicting 1-Year Mortality in Patients With Chronic Liver Failure and Hepatic Encephalopathy
Jing-tao Qin, Xue-ming Zhang, Kai Liu, Yi-shan He, Shu-qin Zheng, Yuan Xue
Cureus.2026;[Epub] CrossRef
Plasma exchange and abrogation of monocyte activation in Wilson’s disease: Letter to the editor on “Acute-on-chronic liver failure: Terminology, mechanisms and management”
Kwon Yong Tak, Min Seo Park, Pil Soo Sung
Clinical and Molecular Hepatology.2026; 32(3): e269. CrossRef
Rethinking ACLF prognosis: Can machine learning outperform conventional scores?: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures”
Jung Hee Kim
Clinical and Molecular Hepatology.2026; 32(3): 1383. CrossRef
The integration of network pharmacology and multiomics reveals the mechanism by which Malus hupehensis leaves inhibit acute liver injury
Jia-xin Qiao, Shu-jie Lv, Bing-tao Zhai, Xiu-lin Zhang, Jiang-xue Cheng, Jing Sun, Xiao-fei Zhang, Dong-yan Guo
BMC Complementary Medicine and Therapies.2026;[Epub] CrossRef
Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review
Guangwen Cao, Haonan Zhao, Guo Lin, Junxiu Chen, Cong Gao, Nahum Méndez-Sánchez, Fei Gao, Xingshun Qi
Advances in Therapy.2026;[Epub] CrossRef
Integrated biomarkers and renal Doppler for early acute kidney injury diagnosis in hepatitis C virus cirrhosis
Amira A A Othman, Magy Magdy Mohamed, Mona Mahmoud Eladl, Fatma M Attia Elsayed
World Journal of Nephrology.2026;[Epub] CrossRef
Acute-on-chronic liver failure following pneumonia in an elderly woman with metabolic dysfunction-associated steatotic liver cirrhosis
Luyi Yao, Kunimichi Saeki, Akane Tange, Takahiro Chigira, Yasushi Ohnisi, Toshinori Takada, Tatsuo Kanda
Clinical Journal of Gastroenterology.2026;[Epub] CrossRef
Baseline CALLY index is associated with all-cause mortality in HBV-ACLF patients receiving ALSS therapy
Wanlong Ma, Jinhua Yuan, QiuYan Chen, Xia Wang, Le Zhang, Yanghua Ou, Yun Jiao, XiangChun Ding
Frontiers in Medicine.2026;[Epub] CrossRef
Spontaneous bacterial peritonitis and soft tissue healing after tooth extraction in liver cirrhosis patients
Gustavo Souza Galvão, Juliana Bertoldi Franco, Maria Paula Siqueira de Melo Peres, Gabriela Bănacu Melo, Jefferson R. Tenório, Janaina B. Medina, Camila de Barros Gallo, Karem L. Ortega
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2025; 139(2): 177. CrossRef
aCCI‐HBV‐ACLF: A Novel Predictive Model for Hepatitis B Virus‐Related Acute‐On‐Chronic Liver Failure
Xinyi Chen, Feiqiong Gao, Qiaoling Pan, Chenjie Huang, Rui Luo, Xiaoqing Lu, Xiaoxiao Chen, Tan Li, Haijun Huang, Jian Wu, Jiong Yu, Lanjuan Li, Hongcui Cao
Alimentary Pharmacology & Therapeutics.2025; 61(2): 286. CrossRef
A Novel Multi-organ Male Model of Alcohol-induced Acute-on-chronic Liver Failure Reveals NET-mediated Hepatocellular Death, Which is Prevented by RIPK3 Inhibition
Martí Ortega-Ribera, Yuan Zhuang, Mrigya Babuta, Veronika Brezani, Radhika S. Joshi, Zsuzsanna Zsengeller, Prashanth Thevkar Nagesh, Yanbo Wang, Roderick Bronson, Gyongyi Szabo
Cellular and Molecular Gastroenterology and Hepatology.2025; 19(4): 101446. CrossRef
Distribution, Drug Resistance, and Risk Factors of Infection in Liver Transplant Recipients With Liver Failure
Wenjing Wang, Bo Wang, Ting Lin, Yi Zhang, Xiaogang Zhang
Transplantation Proceedings.2025; 57(2): 305. CrossRef
Clinical Utility of the Trajectory of Serum Bilirubin and International Normalized Ratio Values in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
Ya-qi Song, Xin-yu Fu, Si-yan Yan, Rong-bin Qi, Yi-jing Zhou, Jia-wei Liang, Jin-qiu Zhang, Li-ping Ye, Xin-li Mao, Shao-wei Li
International Journal of General Medicine.2025; Volume 18: 643. CrossRef
FNDC5/Irisin exacerbates APAP-induced acute liver injury through activating JNK/NF-κB and inflammatory response
Qian-hui Zhang, Lei-ming Jin, Meng-sha Lin, Min-xiu Wang, Ya-qian Cui, Jia-xi Ye, Yong-qiang Xiong, Wu Luo, Wei-wei Zhu, Guang Liang
Acta Pharmacologica Sinica.2025; 46(7): 1946. CrossRef
A Clinical Predictive Model Based on SOCS3 Promoter Methylation to Predict the Prognosis of Acute-on-Chronic Hepatitis B Liver Failure
Ji-Hui Li, Yuna Tang, Jing Wang, Xue-Fei Wei, Na Wang, Jing-Wei Wang, Hui Lyu, Xue-Mei Jiang, Hui-Hui Liu, Kai Wang
Journal of Inflammation Research.2025; Volume 18: 3741. CrossRef
Comparison of Open Albumin Dialysis (OPAL) With Prometheus Fractionated Plasma Separation and Adsorption (FPSA) and Standard Medical Treatment for Acute‐On‐Chronic Liver Failure
Justa Friebus‐Kardash, Amina Louzi, Andreas Kribben, Hartmut H. Schmidt, Michael Jahn, Bartosz Tyczynski, Jassin Rashidi‐Alavijeh, Andreas Schütte, Amos Zeller
Artificial Organs.2025; 49(6): 997. CrossRef
Gasdermin D deletion prevents liver injury and exacerbates extrahepatic damage in a murine model of alcohol-induced ACLF
Martí Ortega-Ribera, Yuan Zhuang, Veronika Brezani, Radhika S Joshi, Zsuzsanna Zsengeller, Prashanth Thevkar Nagesh, Aditi Datta, Gyongyi Szabo
eGastroenterology.2025; 3(1): e100151. CrossRef
Association between lactate-to-albumin ratio and mortality in hepatic failure: a retrospective cohort study
Huan Wu, Long Wu, Li Luo, Hai-yang Li, Bao-fang Zhang
BMC Infectious Diseases.2025;[Epub] CrossRef
Efficacy of a novel artificial liver versatile plasma purification system in patients with acute-on-chronic liver failure
Zhong-Shang Dai, Min Zhang, Yuan-Ye Deng, Ning Zhou, Yi Tian
World Journal of Gastroenterology.2025;[Epub] CrossRef
A nomogram for predicting early biliary complications in adult liver recipients of deceased donor grafts: Integrating artery resistive index and clinical risk factors
Zepeng Lin, Xue Ma, Haibin Ji, Yibo Hou, Xiaoshun He, Xiaofeng Zhu, Anbin Hu
Surgery.2025; 182: 109352. CrossRef
Efficacy and safety of mesenchymal stem cell therapy in acute on chronic liver failure: a systematic review and meta-analysis of randomized controlled clinical trials
Wenming Lu, Longxiang Yan, Lulu Peng, Xuesong Wang, Xingkun Tang, Jing Du, Jing Lin, Zhengwei Zou, Lincai Li, Junsong Ye, Lin Zhou
Stem Cell Research & Therapy.2025;[Epub] CrossRef
The prognostic value of sarcopenia in acute-on-chronic liver failure: a systematic review and meta-analysis
Sike He, Chang-Hai Liu, Yuan Wang, Ziqi Li, Zhenhua Liu, Hao Zeng, Guangxi Sun
BMC Gastroenterology.2025;[Epub] CrossRef
S100A9/RAGE pathway regulation of mitophagy and the effect of JianPi LiShi YangGan formula in acute-on-chronic liver failure
Jing Li, Rui Hu, Xingning Liu, Lanfen Peng, Jinyu Yi, Xin Zhong, Qi Huang, Jialing Sun, Wenxing Feng, Wenfeng Ma, Xiaozhou Zhou
Journal of Ethnopharmacology.2025; 348: 119887. CrossRef
Síndrome hepatopulmonar e hipertensión portopulmonar: conceptos actuales
Julián Rondón-Carvajal, Pierce Sebastián Oliveros-Serrano, Sara Gutiérrez- Vélez, Lorenzo Daniel Chaparro-Galarza, Fernanda Daniela Parra-Guardia
Hepatología.2025; 6(2): 86. CrossRef
CD45+ erythroid progenitor cells as potential biomarkers for disease progression in hepatitis B virus-related acute-on-chronic liver failure
Nan Zhang, Hai-Shi Wu, Xiu-Qing Pang, Cheng-You Yu, Xing Li, Zhi-Liang Gao
BMC Gastroenterology.2025;[Epub] CrossRef
Association between early antibiotic treatment after admission and mortality of acute-on-chronic liver failure patients with bacterial infection: A multicenter retrospective study
Xinyi Chen, Wenyi Chen, Jiahang Zhou, Jingyi Chen, Guoqiang Cao, Chenjie Huang, Xiaoqing Lu, Xiaoxiao Chen, Rui Luo, Haijun Huang, Qiaoling Pan, Jinfeng Yang, Jiong Yu, Hongcui Cao
Virulence.2025;[Epub] CrossRef
Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy
Ji-Hui Li, Jing Wang, Han-Xu Zhu, Feng Zhang, Yu-Na Tang, Jing-Wei Wang, Yu-Chen Fan, Hui-Hui Liu, Kai Wang
Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Research progress of hepatitis B virus and its vaccine
Zhenghuai Huang, J. Xiao, L. Wang, Q. Liang
BIO Web of Conferences.2025; 182: 02005. CrossRef
Etiology, clinical features, and outcomes in acute-on-chronic liver failure patients in the intensive care unit of a quaternary care center
Saleem Sharieff, Fariha Khan, Wajid Ali Rafai, Arslan Saleem Chughtai, Burhan Ahmed, Umar Farooq
Journal of Shalamar Medical & Dental College - JSHMDC.2025; 6(1): 35. CrossRef
The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure
Xiaojing Qin, Shuang Wang, Zhanyao Yan, Ninghui Zhao, Jia Yao
Frontiers in Microbiology.2025;[Epub] CrossRef
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer’s Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition
Zhitong Wang, Zhiling Zhang, Jing Shi, Rongsheng Zhao
Molecular Neurobiology.2025; 62(11): 13999. CrossRef
Panose prevents acute-on-chronic liver failure by reducing bacterial infection in mice
Jiaxin Li, Shihao Xie, Meiling Chen, Changze Hong, Yuqi Chen, Fengyuan Lyu, Niexin Tang, Tianqi Chen, Lingyan Zhao, Weihao Zou, Hongjuan Peng, Jingna Bao, Peng Gu, Bernd Schnabl, Jinjun Chen, Peng Chen
Journal of Clinical Investigation.2025;[Epub] CrossRef
Cytoprotective effect of prostacyclin on hepatic ischemia-reperfusion injury
Christina Mouratidou, Efstathios T Pavlidis, Georgios Katsanos, Maria Papaioannou, Argyri Niti, Serafeim-Chrysovalantis Kotoulas, Georgios Tsoulfas, Eleni Mouloudi, Ioannis N Galanis, Theodoros E Pavlidis
World Journal of Methodology.2025;[Epub] CrossRef
Construction of a predictive model for concurrent infection in liver failure patients based on prognostic nutritional index and inflammatory cytokine analysis
Hong Yang, Bin Zhang, Chun Yu, Xiao Zhu
BMC Gastroenterology.2025;[Epub] CrossRef
Comparative liver proteomic analysis of protein expression changes in an acute-on-chronic liver failure mouse model
Keyin Wang, Zhuolin Zou, Dahai Wei
European Journal of Inflammation.2025;[Epub] CrossRef
Shining light on liquid–liquid phase separation in chronic liver disease
Ming-Hui Li, Yang Yang, Qi-Qi Dong, Wen-Jie Sun, Hui Tao, Jing-Jing Yang
Drug Discovery Today.2025; 30(10): 104464. CrossRef
Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study
Junyeol Kim, Kyeongmin Lee, Jiyeon Oh, Hayeon Lee, Jong-In Chang, Tae Young Park, Dong Keon Yon, Hyoung-Chul Oh
The Korean Journal of Internal Medicine.2025; 40(5): 747. CrossRef
Analysis of the Cost-Effectiveness of Treatment Strategies for Acute-on-Chronic Liver Failure
Wei-Bo Guo, Xi-Ju Guo, Meng-Yao Zheng, Xuan-Cheng Xie, Yong-Pin Wang, Bo Gan, Jin-Hui Yang
Transplantation Proceedings.2025; 57(8): 1554. CrossRef
Prognostic value of dynamic changes in C-reactive protein to albumin ratio in patients with acute-on-chronic liver failure
Zong-Yi Zhu, Li-Juan Yan
World Journal of Hepatology.2025;[Epub] CrossRef
Machine Learning Prediction of 90‐Day Mortality in HBV‐Related ACLF Using Olink‐Derived Inflammatory Protein Signatures
Yi Zhang, Lina Sun, Huimin Liu, Ke Shi, Yu Lu, Ying Feng, Xianbo Wang
Liver International.2025;[Epub] CrossRef
Effects of different therapeutic methods on the 90-day prognosis of patients with HBV-ACLF: A systematic review and network meta-analysis
Yin Hua, Huaqiang Liu, Yuqin He, Shousheng Liu, Yongning Xin
Medicine.2025; 104(51): e46388. CrossRef
miR-223-3p predicts prognosis of hepatitis B virus-related acute-on-chronic liver failure and is involved in hepatocyte injury via HSP90B1
Feiyue Xie, Qiuping Ren, Jun He, Menghang Wu
Hereditas.2025;[Epub] CrossRef
Mesenchymal stem cell–derived exosome delivery of let-7a-5p enhances macrophage efferocytosis via Arid3a/Mertk axis in acute-on-chronic liver failure
Junyi Wang, Zhihui Li, Zhouhan Wang, Wei Liang, Shibo Meng, Junfeng Chen, Jialei Wang, Jing Zhang, Bingliang Lin
Stem Cells Translational Medicine.2025;[Epub] CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Evaluation of the prognosis of hepatitis B virus-associated acute-on-chronic liver failure patients using a combined model for end-stage liver disease score with blood ammonia, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferas
Yan Wang, Li Chen, Wei Sun, Wenting Li, Ying Xu, Jing Gu, Jianhe Gan
Medicine.2025; 104(49): e45987. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Hepatoprotective efficacy and interventional mechanism of JianPi LiShi YangGan formula in acute-on-chronic liver failure
Jing Li, Qi Huang, Wenfeng Ma, JinYu Yi, Xin Zhong, Rui Hu, Jialing Sun, MengQing Ma, Minling Lv, Zhiyi Han, Wei Zhang, Wenxing Feng, Xinfeng Sun, Xiaozhou Zhou
Journal of Ethnopharmacology.2024; 318: 116880. CrossRef
Causal Relationship between Angina and Hepatic Failure as Revealed by Mendelian Randomization
Fengming Xu, Olaf Dirsch, Uta Dahmen
Journal of Clinical Medicine.2024; 13(2): 449. CrossRef
Visualization of therapeutic intervention for acute liver injury using low-intensity pulsed ultrasound-responsive phase variant nanoparticles
You Yang, Ju-ying Zhang, Zi-jun Ma, Shi-chun Wang, Ping He, Xiao-qing Tang, Chao-feng Yang, Xia Luo, Xing Yang, Ling Li, Mao-chun Zhang, Yang Li, Jin-hong Yu
Biomaterials Science.2024; 12(5): 1281. CrossRef
The Free Triiodothyronine, Gamma-Glutamyl Transpeptidase and Spontaneous Bacterial Peritonitis Index: A Novel Model for Predicting 1-Year Mortality in Patients with HBV-Related Hepatic Encephalopathy
Lin Lin, Ze-yu Huang, Kai Liu, Xue-cheng Tong, Zhi-xin Zhang, Yuan Xue
Hepatic Medicine: Evidence and Research.2024; Volume 16: 1. CrossRef
Characteristics and risk factors for invasive fungal infection in hospitalized patients with acute-on-chronic hepatitis B liver failure: a retrospective cohort study from 2010 to 2023
Yin-Ping Wu, Feng-Cai Li, Hang-Yu Ma, Xue-Yan Yang, Jing Zuo, Yu-Xin Tian, Li Lv, Kai Wang, Yu-Chen Fan
Frontiers in Microbiology.2024;[Epub] CrossRef
Decompensated cirrhosis and antibiotic prophylaxis: striking a delicate balance
Jung Gil Park
The Korean Journal of Internal Medicine.2024; 39(3): 369. CrossRef
Polyethylene Terephthalate Fiber Modified with Type I Collagen as a 3D Scaffold Material for Bioartificial Liver
Yang Li, Yang Zhang, Jianping Gao, Shuguang Liao, Guifeng Zhang
Applied Sciences.2024; 14(11): 4537. CrossRef
IRGM/Irgm1 increases autophagy to inhibit activation of NLRP3 inflammasome in inflammatory injury induced acute liver failure
Xing Zhang, Yangyang Hu, Wei Wang, Ru Ji, Ziyue Li, Weiyan Yu, Zhinian Wu, Ying Xiao, Tingyu Guo, Zeqiang Qi, Yadong Wang, Caiyan Zhao
Cell Death Discovery.2024;[Epub] CrossRef
Liver transplantation consideration and evaluation: a life-saving treatment in acute-on-chronic liver failure
Andrew Johnson, Shahid Habib
Exploration of Digestive Diseases.2024; : 262. CrossRef
Baicalein upregulates macrophage TREM2 expression via TrKB-CREB1 pathway to attenuate acute inflammatory injury in acute-on-chronic liver failure
Jia Chen, Qiongchi Zhang, Wenxiong Xu, Zhipeng Li, Xiyao Chen, Qiumin Luo, Dong Wang, Liang Peng
International Immunopharmacology.2024; 139: 112685. CrossRef
Acute decompensation and acute-on-chronic liver failure
Sencan Acar
Exploration of Digestive Diseases.2024; : 275. CrossRef
Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats
Shao-Jung Hsu, Kuang-Yao Yang, Hui-Chun Huang, Chiao-Lin Chuang, Ching-Chih Chang, Chon-Kit Pun, Ming-Chih Hou, Fa-Yauh Lee
European Journal of Pharmacology.2024; 980: 176817. CrossRef
Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute‐on‐chronic liver failure due to hepatitis B: A meta‐analysis
Le Zhang, Yan Ma, Xia Wang, Li‐Na Ma, Wanlong Ma, Xiang‐Chun Ding
Journal of Clinical Apheresis.2024;[Epub] CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
Do Seon Song, Dong Joon Kim
Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
The Impact of Liver Failure on the Immune System
Alicja Dąbrowska, Bartosz Wilczyński, Jakub Mastalerz, Julia Kucharczyk, Julita Kulbacka, Anna Szewczyk, Nina Rembiałkowska
International Journal of Molecular Sciences.2024; 25(17): 9522. CrossRef
Pathophysiological features of acute liver failure caused by cholestasis [
I.V. Kolosovych, I.V. Hanol, Y.O. Nesteruk
Fiziolohichnyĭ zhurnal.2024; 70(4): 80. CrossRef
Outcomes of emergency pediatric ABO-incompatible living donor liver transplantation in Korea
Sunghyo An, Jongman Kim, Sang Jin Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2024; 4(2): 63. CrossRef
Circulating copeptin level and the clinical prognosis of patients with chronic liver disease
Hao-Qian Tan, Ming Zhao, Zan Huang, Yang Liu, Han Li, Long-Hui Ma, Jun-Ying Liu
World Journal of Gastroenterology.2023; 29(31): 4797. CrossRef

25,789 View
1,201 Download
99 Web of Science
Crossref

Original Article

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus: Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun; Clin Mol Hepatol 2022;28(4):912-925.
Published online July 28, 2022; DOI: https://doi.org/10.3350/cmh.2022.0121

Background/Aims
Acute-on-chronic liver failure (ACLF) is a catastrophic illness. Few studies investigated the prognostic value of vitamin D-binding protein (VDBP) for hepatitis B virus (HBV)-related ACLF (HBV-ACLF) resulted in conflicting results.
Methods
Two prospective HBV-ACLF cohorts (n=287 and n=119) were enrolled to assess and validate the prognostic performance of VDBP.
Results
VDBP levels in the non-survivors were significantly lower than in the survivors (P<0.001). Multivariate Cox regression demonstrated that VDBP was an independent prognostic factor for HBV-ACLF. The VDBP level at admission gradually decreased as the number of failed organs increased (P<0.001), and it was closely related to coagulation failure. The areas under the receiver operating characteristic curve (AUCs) of the Child-Pugh-VDBP and chronic liver failuresequential organ failure assessment (CLIF–SOFA)-VDBP scores were significantly higher than those of Child-Pugh (P<0.001) and CLIF-SOFA (P=0.0013). The AUCs of model for end-stage liver disease (MELD)-VDBP were significantly higher than those of MELD (P= 0.0384) only in the case of cirrhotic HBV-ACLF patients. Similar results were validated using an external multicenter HBV-ACLF cohort. By longitudinal observation, the VDBP levels gradually increased in survivors (P=0.026) and gradually decreased in non-survivors (P<0.001). Additionally, the VDBP levels were found to be significantly decreased in the deterioration group (P=0.012) and tended to be decreased in the fluctuation group (P=0.055). In contrast, they showed a significant increase in the improvement group (P=0.036).
Conclusions
The VDBP was a promising prognostic biomarker for HBV-ACLF. Sequential measurement of circulating VDBP shows value for the monitoring of ACLF progression.

Citations

Citations to this article as recorded by

Vitamin D deficiency in chronic hepatitis B across the disease spectrum: association with viral activity rather than hepatocellular carcinoma
Dr Tufael, Abu Bakar Siddique, Md Haroon Or Rashid, Mohd Hasan Mujahid, Nabil Deb Nath, Asim Debnath, Most Farhana Akter, Md. Robiul Islam, Vijay Jagdish Upadhye
BMC Gastroenterology.2026;[Epub] CrossRef
Integrated routine laboratory indices for risk stratification in HBV-related cirrhosis: a real-world study
Lin Zhang, Liang Li, Xiaowei Du, Suhua Pang, Youde Yan, Zhenjiang Zhang
BMC Gastroenterology.2026;[Epub] CrossRef
Omics in acute‐on‐chronic liver failure
Peng Li, Xi Liang, Jinjin Luo, Jun Li
Liver International.2025;[Epub] CrossRef
Deficiency of vitamin D-binding protein exacerbates liver fibrosis by disrupting iron homeostasis via the activation of YAP signaling
Qing Zheng, Qingquan Tan, Dan Wang, Yanling Ma, Yanni Zhou, Yonghua Chen, Dan Long, Jiayin Yang, Li Feng
Experimental Cell Research.2025; 452(2): 114767. CrossRef
miR-223-3p predicts prognosis of hepatitis B virus-related acute-on-chronic liver failure and is involved in hepatocyte injury via HSP90B1
Feiyue Xie, Qiuping Ren, Jun He, Menghang Wu
Hereditas.2025;[Epub] CrossRef

9,476 View
168 Download
5 Web of Science
Crossref

Snapshot

Liver fibrosis, cirrhosis, and portal hypertension

Acute on chronic liver failure in cirrhosis: Marta Tonon, Salvatore Piano; Clin Mol Hepatol 2022;28(2):273-275.
Published online February 14, 2022; DOI: https://doi.org/10.3350/cmh.2022.0036

Citations

Citations to this article as recorded by

From Liver to Brain: A 2.5D Deep Learning Model for Predicting Hepatic Encephalopathy Using Opportunistic Non-contrast CT in Hepatitis B Related Acute-on-Chronic Liver Failure Patients
Zonglin Liu, Xueyun Zhang, Ying Chen, Qi Zhang, Zhenxuan Ma, Yue Wu, Yuxin Huang, Yajie Li, Xi Zhao, Wenchao Gu, Jiaxing Wu, Ying Tao, Yuxin Shi, Zhenwei Yao, Yan Ren, Yuxian Huang, Shiman Wu
Journal of Imaging Informatics in Medicine.2026;[Epub] CrossRef
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
Journal of Korean Medical Science.2026;[Epub] CrossRef
Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
RAC1 as a novel therapeutic target for acute liver failure
Barbara Bueloni, Esteban Fiore, María José Cantero, Lucia Lameroli, Catalina Atorrasagasti, Matías Ciarlantini, Andrea Barquero, Lucía Gandolfi Donadio, Daiana Ganiewich, Francisco Orozco, Martín Fauda, Julieta Comin, Ali Canbay, Juan Bayo, Guillermo Mazz
JHEP Reports.2025; 7(11): 101547. CrossRef
Akkermansia muciniphila improve cognitive dysfunction by regulating BDNF and serotonin pathway in gut-liver-brain axis
Eun Ji Kang, Min-Gi Cha, Goo-Hyun Kwon, Sang Hak Han, Sang Jun Yoon, Sang Kyu Lee, Moo Eob Ahn, Sung-Min Won, Eun Hee Ahn, Ki Tae Suk
Microbiome.2024;[Epub] CrossRef
Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, G
Clinical and Molecular Hepatology.2024; 30(4): 845. CrossRef
Alterations in the intestinal microbiome and metabolic profile of patients with cirrhosis supplemented with lactulose, Clostridium butyricum, and Bifidobacterium longum infantis: a randomized placebo-controlled trial
Haifeng Lu, Xiaofei Zhu, Lingyun Wu, Xiaobin Lou, Xiaxia Pan, Bowen Liu, Hua Zhang, Lingxiao Zhu, Lanjuan Li, Zhongwen Wu
Frontiers in Microbiology.2023;[Epub] CrossRef

15,940 View
275 Download
6 Web of Science
Crossref

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats: Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee; Clin Mol Hepatol 2022;28(2):232-241.
Published online January 5, 2022; DOI: https://doi.org/10.3350/cmh.2021.0141

Background/Aims
Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy.
Methods
Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy.
Results
Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls.
Conclusion
Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.

Citations

Citations to this article as recorded by

Cirrhotic cardiomyopathy: pathophysiology, assessment, and implications for liver transplantation
Madeleine Gill, Anoop N. Koshy, Jeyamani Ramachandran, Geoffrey W. McCaughan, Avik Majumdar
Therapeutic Advances in Gastroenterology.2026;[Epub] CrossRef
Heart failure with preserved ejection fraction beyond the heart: exploring the heart–liver–pancreas axis
Han Naung Tun, Omar Rahal, Ivan R Figueroa Baez, Omar Santana-Sánchez, Timothy Gardner
ESC Heart Failure.2026;[Epub] CrossRef
Bile duct ligation impairs function and expression of breast cancer resistance protein in rat blood-retinal barrier mainly due to both the increased ammonia and bilirubin
Zijin Lin, Runze Wu, Yiting Yang, Mingrui Ji, Xiaodong Liu, Li Liu, Hanyu Yang
Drug Metabolism and Disposition.2026; 54(5): 100282. CrossRef
Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy
Fengxue Yu, Dae Gon Ryu, Ki Tae Yoon, Hongqun Liu, Samuel S. Lee
International Journal of Molecular Sciences.2025; 26(13): 6423. CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era
Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran
Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
Galectin-3: A Multitasking Protein Linking Cardiovascular Diseases, Immune Disorders and Beyond
Mariarosaria Morello, Gisella Titolo, Saverio D’Elia, Silvia Caiazza, Ettore Luisi, Achille Solimene, Chiara Serpico, Andrea Morello, Francesco Natale, Paolo Golino, Plinio Cirillo, Giovanni Cimmino
Targets.2025; 3(4): 34. CrossRef
Galectin-3 as a therapeutic target in pulmonary hypertension: Molecular mechanisms, drug development directions, and emerging clinical applications
Antonín Sedlář, Pavla Bojarová, František Kolář, Vladimír Křen, Lucie Bačáková
Biomedicine & Pharmacotherapy.2025; 193: 118756. CrossRef
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care
Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee
JHEP Reports.2024; 6(1): 100911. CrossRef
Cirrhotic cardiomyopathy: Pathogenesis, clinical features, diagnosis, treatment and prognosis
Francisca Almeida, Alexandra Sousa
Revista Portuguesa de Cardiologia.2024; 43(4): 203. CrossRef
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities
Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee
International Journal of Molecular Sciences.2024; 25(11): 5849. CrossRef
Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy
Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee
Pharmaceuticals.2023; 16(7): 978. CrossRef
Chenodeoxycholic Acid Improves Embryo Implantation and Metabolic Health through Modulating Gut Microbiota–Host Metabolites Interaction during Early Pregnancy
Meixia Chen, Ying Zhao, Haifeng Ji, Lu Li, Hui Liu, Sixin Wang, Dongyan Zhang, Jingdong Yin, Jing Wang, Xin Zhang
Antioxidants.2023; 13(1): 8. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study
Melisa Cetin, Ping Yip, Zhou-Hao Liu
Future Healthcare Journal.2023; 10: S18. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study
Melisa Cetin, Ping Yip, Wing Sze Leung, Zhou-Hao Liu
Clinical Medicine.2023; 23(6): 81. CrossRef
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy
Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee
Frontiers in Network Physiology.2022;[Epub] CrossRef
Collagen-binding fibroblast growth factor ameliorates liver fibrosis in murine bile duct ligation injury
Qiangqiang Shi, Susu Wei, Zhi Chao Li, Jing Xu, Yaxin Li, Chuanlong Guo, Xianggen Wu, Chunying Shi, Guohu Di
Journal of Biomaterials Applications.2022; 37(5): 918. CrossRef

10,384 View
147 Download
12 Web of Science
Crossref

Review

Viral hepatitis

Approaches to quantifying hepatitis B virus covalently closed circular DNA: Henrik Zhang, Thomas Tu; Clin Mol Hepatol 2022;28(2):135-149.
Published online October 22, 2021; DOI: https://doi.org/10.3350/cmh.2021.0283

Abstract
PDF

Chronic hepatitis B is a major cause of liver disease worldwide and is currently incurable. Hepatitis B virus (HBV) covalently closed circular (ccc) DNA is a key form of the virus responsible for its persistence and is the transcriptional template for all viral transcripts. The field is focussed on methods to clear HBV cccDNA but this been limited by technical difficulties in its quantification due to: identical sequence to other forms of HBV DNA; low copy number per cell; and high resistance to denaturation by heat, leading to difficulty using polymerase chain reaction or hybridization methods for detection. A number of assays have been developed in order to overcome these hurdles either directly or detecting cccDNA levels indirectly via its transcriptional products. In this review, we summarize the approaches to cccDNA quantification that are currently used, and outline key open questions in the cccDNA biology field which remain to be answered due to the limitations of current methods.

Citations

Citations to this article as recorded by

Development of a Sensitive and Specific RPA-CRISPR/Cas12a Assay for Intrahepatic Quantification of HBV cccDNA
Pattida Kongsomboonchoke, Chaiyaboot Ariyachet, Pornchai Kaewsapsak, Pongserath Sirichindakul, Pisit Tangkijvanich
International Journal of Molecular Sciences.2026; 27(1): 551. CrossRef
Aloe emodin isolated from Cassiae semen upregulates IFITM1 to suppress hepatitis B virus replication via the interferon signaling pathway
Xin Wen, Xincan Yu, Yuxin Hu, Jiamin Chen, Dongwei Zhang, Yalin Hou, Shui Liu, Xuemeng Shi, Jun Xu, Felicia Goodrum
mSphere.2026;[Epub] CrossRef
Serum HBV RNA reflects persistent viral transcriptional activity in nucleos(t)ide analogue-treated patients despite suppressed HBV DNA
Hongfang Gu, Yan Jiao, Yue Pan, Ju Li, Bingxin Xie, Fan Zhang
Diagnostic Microbiology and Infectious Disease.2026; 116(3): 117531. CrossRef
The immunoecology of occult hepatitis B virus infection: genetic remodeling and the immune-mediated microcosm
Feng Wang, Le Wang, Zhiguo Xu, Zequn Ou, Yun Wang, Haiying Yang, Jingxian Fei, Jingxian Song, Yizhu Chen, Ke Lv
Frontiers in Immunology.2026;[Epub] CrossRef
Quantitative Real-Time PCR testing in the control of hepatitis B and C: Progress and challenges towards eradication by 2030
Iulia Patrascu
Acta Marisiensis - Seria Medica.2025; 71(4): 284. CrossRef
Editorial: High qHBsAg—is it a good or bad signal?
Beom Kyung Kim
Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616. CrossRef
Metabolic disorders and hepatitis: Insights from a Mendelian randomization study
Ling-Bo Liang, Xiang-Ping Liu, Ting-Rui Mao, Qiao-Li Su
World Journal of Gastrointestinal Surgery.2024; 16(6): 1775. CrossRef
Detection technology and clinical applications of serum viral products of hepatitis B virus infection
Ying Liu, Di Wu, Kui Zhang, Rongrong Ren, Yuxuan Liu, Shuya Zhang, Xuanyu Zhang, Jilin Cheng, Liping Chen, Jun Huang
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef
New Approaches to Chronic Hepatitis B
Dan L. Longo, Geoffrey Dusheiko, Kosh Agarwal, Mala K. Maini
New England Journal of Medicine.2023; 388(1): 55. CrossRef
Construction of a Lasso regression-based prediction model for development of cirrhosis in chronic hepatitis B
Ying Li, Ke-Xing Han, Qian Su, Nan Xu, Qin-Xiu Xie, Yu-Feng Gao
World Chinese Journal of Digestology.2023; 31(7): 282. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
An RNA-based system to study hepatitis B virus replication and evaluate antivirals
Yingpu Yu, William M. Schneider, Maximilian A. Kass, Eleftherios Michailidis, Ashley Acevedo, Ana L. Pamplona Mosimann, Juliano Bordignon, Alexander Koenig, Christine M. Livingston, Hardeep van Gijzel, Yi Ni, Pradeep M. Ambrose, Catherine A. Freije, Mengy
Science Advances.2023;[Epub] CrossRef
Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors
Phuong Thi Bich Doan, Kouki Nio, Tetsuro Shimakami, Kazuyuki Kuroki, Ying-Yi Li, Saiho Sugimoto, Hideo Takayama, Hikari Okada, Shuichi Kaneko, Masao Honda, Taro Yamashita
Viruses.2023; 15(5): 1178. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B
Thomas Tu, Harout Ajoyan, Jacob George
Clinics in Liver Disease.2023; 27(4): 837. CrossRef
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(3): 794. CrossRef
cccDNA-Targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels
Ee Chee Ren, Nicole Ziyi Zhuo, Zhi Yi Goh, Isabelle Bonne, Benoît Malleret, Hui Ling Ko
Biomolecules.2023; 13(10): 1438. CrossRef
Hepatitis B Virus and microRNAs: A Bioinformatics Approach
Verdiana Zulian, Giulia Fiscon, Paola Paci, Anna Rosa Garbuglia
International Journal of Molecular Sciences.2023; 24(24): 17224. CrossRef
Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA
Thomas Tu, Florian van Bömmel, Thomas Berg
Seminars in Liver Disease.2022; 42(03): 327. CrossRef

14,541 View
412 Download
17 Web of Science
Crossref

Letter to the Editor

Hepatic neoplasm

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma: Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura; Clin Mol Hepatol 2021;27(4):616-619.
Published online September 13, 2021; DOI: https://doi.org/10.3350/cmh.2021.0258

Citations

Citations to this article as recorded by

Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma
Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami
Journal of Oncology Pharmacy Practice.2026; 32(1): 24. CrossRef
The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi
Internal Medicine.2026; 65(11): 1450. CrossRef
Optimizing Nutrition to Counter Sarcopenia in Hepatocellular Carcinoma: A Narrative Review of Mechanisms, Clinical Consequences, and Supportive Therapeutic Options
Hiroki Tai, Asahiro Morishita, Tomoko Tadokoro, Kyoko Oura, Rie Yano, Mai Nakahara, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara
Nutrients.2026; 18(3): 494. CrossRef
Quality of life in patients with hepatocellular carcinoma: a bibliometric analysis
Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
Discover Oncology.2026;[Epub] CrossRef
Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib
Hideki Iwamoto, Shigeo Shimose, Hironori Koga, Takumi Kawaguchi
Journal of Liver Cancer.2026; 26(1): 83. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
Hepatology International.2025; 19(2): 261. CrossRef
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen
Journal of Hematology & Oncology.2024;[Epub] CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib
Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, Eri Kuboyama, Hideki Iwamoto, Masatoshi Tanaka, Etusko Moriyama, Tomotake Shirono, Kota Takaki, Yu Noda, Masahito Nakano, Mitsutoshi Inoue, Kazuki Tsustumi, Ryoko Kuromatsu, Hironori Koga, Kyoko Higuchi, Taku
Journal of Gastroenterology and Hepatology.2023; 38(7): 1140. CrossRef
Correlation between branched-chain amino acids intake and total lymphocyte count in head and neck cancer patients: a cross-sectional study
Yosua Yan Kristian, Rahmat Cahyanur, Yohannessa Wulandari, Wina Sinaga, Widjaja Lukito, Findy Prasetyawaty, Wiji Lestari
BMC Nutrition.2023;[Epub] CrossRef

9,510 View
216 Download
10 Web of Science
Crossref

Editorials

Hepatic neoplasm

Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma: Jaewhan Song; Clin Mol Hepatol 2020;26(4):484-486.
Published online October 1, 2020; DOI: https://doi.org/10.3350/cmh.2020.0220

Citations

Citations to this article as recorded by

ABCG8‑mediated sterol efflux increases cancer cell progression via the LRP6/Wnt/β‑catenin signaling pathway in radiotherapy‑resistant MDA‑MB‑231 triple‑negative breast cancer cells
Young Ko, Ju Won, Hana Jin, Nam Nguyen, Yaeram Won, Vedaste Nsanzimana, Seung Yun, Sang Park, Hye Kim
International Journal of Molecular Medicine.2025; 55(5): 1. CrossRef
Clinical significance of PNO1 as a novel biomarker and therapeutic target of hepatocellular carcinoma
Sanjit K. Roy, Shivam Srivastava, Caroline McCance, Anju Shrivastava, Jason Morvant, Sharmila Shankar, Rakesh K. Srivastava
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT
Yen-Nien Liu, Wei-Yu Chen, Hsiu-Lien Yeh, Wei-Hao Chen, Kuo-Ching Jiang, Han-Ru Li, Phan Vu Thuy Dung, Zi-Qing Chen, Wei-Jiunn Lee, Michael Hsiao, Jiaoti Huang, Yu-Ching Wen
Science Signaling.2024;[Epub] CrossRef
Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights
Fereshteh Rahdan, Alihossein Saberi, Neda Saraygord-Afshari, Morteza Hadizadeh, Tahura Fayeghi, Elham Ghanbari, Hassan Dianat-Moghadam, Effat Alizadeh
Heliyon.2024; 10(20): e39489. CrossRef
PIM1-Induced Cytoplasmic Expression of RBMY Mediates Hepatocellular Carcinoma Metastasis
Huey-Huey Chua, Mei-Hwei Chang, Ya-Hui Chen, Daw-Jen Tsuei, Yung-Ming Jeng, Po-Huang Lee, Yen-Hsuan Ni
Cellular and Molecular Gastroenterology and Hepatology.2023; 15(1): 121. CrossRef
Clinical Significance of Combined Epithelial–Mesenchymal Transition Markers Expression and Role of Rac1 in Hepatocellular Carcinoma
Seung Kak Shin, Sujin Ryu, Seungyoon Nam, Seung Yeon Ha, Oh Sang Kwon, Yun Soo Kim, Se-Hee Kim, Ju Hyun Kim
International Journal of Molecular Sciences.2023; 24(2): 1765. CrossRef
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
Shuo Deng, Hin Chong Leong, Arpita Datta, Vennila Gopal, Alan Prem Kumar, Celestial T. Yap
Cancers.2022; 14(7): 1652. CrossRef
Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma
Yu-Cheng Lee, Cheng-Han Lin, Wei-Lun Chang, Wen-Der Lin, Jhih-Kai Pan, Wei-Jan Wang, Bor-Chyuan Su, Hsien-Hui Chung, Chen-Hsun Tsai, Forn-Chia Lin, Wen-Ching Wang, Pei-Jung Lu
International Journal of Molecular Sciences.2022; 23(8): 4367. CrossRef
Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma
Tian-Huei Chu, Chou-Yuan Ko, Po-Han Tai, Yi-Chen Chang, Chao-Cheng Huang, Tung-Yang Wu, Hoi-Hung Chan, Ping-Hsuan Wu, Chien-Hui Weng, Yu-Wei Lin, Mei-Lang Kung, Cheng-Chieh Fang, Jian-Ching Wu, Zhi-Hong Wen, Yung-Kuo Lee, Tsung-Hui Hu, Ming-Hong Tai
Journal of Biological Chemistry.2022; 298(10): 102442. CrossRef
MiR-23b-3p suppresses epithelial-mesenchymal transition, migration, and invasion of hepatocellular carcinoma cells by targeting c-MET
Na Ri Park, Jung Hoon Cha, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Si Hyun Bae
Heliyon.2022; 8(10): e11135. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef

10,613 View
152 Download
11 Web of Science
Crossref

Acute liver injury and Acute liver failure

Acute-on-chronic liver failure: A predictor of poor prognosis in patients with variceal bleeding or a risk factor for variceal bleeding?: Nae-Yun Heo; Clin Mol Hepatol 2020;26(4):487-488.
Published online October 1, 2020; DOI: https://doi.org/10.3350/cmh.2020.0209

Citations

Citations to this article as recorded by

Risk of Variceal Hemorrhage in Patients With Cirrhosis Taking Calcium-Channel Blockers
Junlong Dai, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai
Clinical Gastroenterology and Hepatology.2026; 24(8): 2215. CrossRef
Predicting the gastrointestinal bleeding of HBV-related acute-on-chronic liver failure based on machine learning
Jiwei Fu, Ahao Wu, Ziwei Zhou, Ting Deng, Pei Shi, Wentao Zhu, Mengyu Tao, Yuyu Zeng, Yuchen Peng, Yuna Wang, Xiaoping Wu
Frontiers in Medicine.2025;[Epub] CrossRef
Acute-on-chronic liver failure is independently associated with higher mortality for cirrhotic patients with acute esophageal variceal hemorrhage: Retrospective cohort study
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost Jr, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balb
World Journal of Clinical Cases.2023; 11(17): 4003. CrossRef
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clinical and Molecular Hepatology.2022; 28(3): 540. CrossRef

9,161 View
126 Download
4 Web of Science
Crossref

First

Page of 3

Last

Page Path

"AI"

Article category

Keywords

Publication year

Article category

Keywords

Publication Year

Funded articles

"AI"

Review

Correspondence

Letter to the Editor

Review

Correspondence

Editorial

Letter to the Editor

Correspondence

Editorial

Research Letter

Correspondence

Editorial

Original Article

Letter to the Editor

Research Letter

Editorial

Original Article

Correspondence

Review

Correspondence

Reply to Correspondence

Viral hepatitis

Original Articles

Reviews

Liver Transplantation

Editorials

Steatotic liver disease

Correspondence

Steatotic liver disease

Original Articles

Steatotic liver disease

Viral hepatitis

Correspondence

Acute liver injury and Acute liver failure

Editorial

Acute liver injury and Acute liver failure

Correspondence

Hepatic neoplasm

Original Article

Acute liver injury and Acute liver failure

Correspondence

Viral hepatitis

Editorial

Viral hepatitis

Letter to the Editor

Artificial intelligence, epidemiology, methodology, or others

Review

Steatotic liver disease

Letter to the Editor

Artificial intelligence, epidemiology, methodology, or others

Editorial

Hepatic neoplasm

Review

Acute liver injury and Acute liver failure

Original Article

Snapshot

Liver fibrosis, cirrhosis, and portal hypertension

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

Review

Viral hepatitis

Letter to the Editor

Hepatic neoplasm

Hepatic neoplasm

Acute liver injury and Acute liver failure

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS